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The Ebola virus (EBOV) is a member of the family, Filoviridae, and is the etiological agent of Ebola
hemorrhagic fever (EHF). This disease causes significant morbidity and mortality in humans and nonhuman primates, with human fatality rates reaching 90% during outbreaks of the Zaire subtype. Currently,
there are no licensed vaccines or antivirals for EBOV and our understanding of viral pathogenesis is
limited. Therefore, further studies examining the pathogenic mechanisms of EBOV are necessary to fully
understand and effectively treat EHF. The main Ebola virus glycoprotein (GP) is the only viral protein found
on the surface of the Ebola virion and is therefore responsible for mediating attachment and entry of the
virus into host cells. However, expression of GP independently of other viral proteins induces dramatic
morphological changes including cell rounding and detachment in those cells expressing GP. This
phenomenon is referred to as GP-mediated cytopathology and is the focus of the work described herein.
We have undertaken studies to identify the mucin domain, a highly glycosylated domain within GP, as
sufficient to cause this cytopathology. We then have used a cell-biological approach to elucidate the
mechanism by which this cytopathology occurs. The mucin domain forms a glycan shield at the plasma
membrane, disrupting the function of host proteins in the vicinity of GP. We then show that GP-mediated
shielding of major histocompatibility complex class I at the cell surface prevents the activation of CD 8+ T
cells. Additionally, GP can sterically shield its own epitopes at the cell surface. This model of steric
hindrance was also found to apply to the surface of pseudoviral particles, where access to a neutralizing
epitope on GP is affected. Our data indicate that the EBOV GP forms a glycan shield with the ability to
block antibody binding and disrupt protein function at the cell and virion surface. This study describes a
novel viral mechanism for the disruption of surface protein function and suggests a possible mechanism
for the evasion of host humoral and cellular immune responses.
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ABSTRACT

A STUDY OF THE EBOLA VIRUS GLYCOPROTEIN: DISRUPTION OF HOST
SURFACE PROTEIN FUNCTION AND EVASION OF IMMUNE REPSONSES
Joseph Richard Francica
Dissertation Supervisor: Paul Bates

The Ebola virus (EBOV) is a member of the family, Filoviridae, and is the
etiological agent of Ebola hemorrhagic fever (EHF). This disease causes significant
morbidity and mortality in humans and non-human primates, with human fatality rates
reaching 90% during outbreaks of the Zaire subtype. Currently, there are no licensed
vaccines or antivirals for EBOV and our understanding of viral pathogenesis is limited.
Therefore, further studies examining the pathogenic mechanisms of EBOV are necessary
to fully understand and effectively treat EHF. The main Ebola virus glycoprotein (GP) is
the only viral protein found on the surface of the Ebola virion and is therefore responsible
for mediating attachment and entry of the virus into host cells. However, expression of
GP independently of other viral proteins induces dramatic morphological changes
including cell rounding and detachment in those cells expressing GP. This phenomenon
is referred to as GP-mediated cytopathology and is the focus of the work described
herein. We have undertaken studies to identify the mucin domain, a highly glycosylated
domain within GP, as sufficient to cause this cytopathology. We then have used a cellbiological approach to elucidate the mechanism by which this cytopathology occurs. The
mucin domain forms a glycan shield at the plasma membrane, disrupting the function of
iv

host proteins in the vicinity of GP. We then show that GP-mediated shielding of major
histocompatibility complex class I at the cell surface prevents the activation of CD 8+ T
cells. Additionally, GP can sterically shield its own epitopes at the cell surface. This
model of steric hindrance was also found to apply to the surface of pseudoviral particles,
where access to a neutralizing epitope on GP is affected. Our data indicate that the EBOV
GP forms a glycan shield with the ability to block antibody binding and disrupt protein
function at the cell and virion surface. This study describes a novel viral mechanism for
the disruption of surface protein function and suggests a possible mechanism for the
evasion of host humoral and cellular immune responses.
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CHAPTER 1 − EBOLA VIRUS LITERATURE REVIEW AND INTRODUCTION
TO EBOLA GLYCOPROTEIN-MEDIATED CYTOPATHOLOGY
1.1

Identification of the Ebola virus
The first documented outbreak of Ebola virus (EBOV) began on September 5th,

1976, at the Yambuku Mission Hospital near Bumba in northern Zaire (now the
Democratic Republic of Congo, DRC). A 44-year-old patient had presented himself to
the hospital 10 days earlier with a febrile illness and was given an injection of
chloroquine for presumptive malaria, which alleviated his fever. However, febrile
symptoms returned on September 1st; 3 days after being admitted to the hospital, the
patient died. By October 24th of that year, 280 fatal human cases of an unknown viral
hemorrhagic fever had been documented around Yambuku, and later Kinsasha, along
with only 38 serologically-confirmed survivors [1].
In the weeks after this index case was reported, an international team of doctors
deployed to the effected region with the following goals: to surveil and contain the
disease, to conduct an epidemiological analysis of its spread, and to begin investigating
the microbial agent behind this novel syndrome. They found that patients often presented
with general symptoms such as fever, headache and sore throat, but showed more critical
signs as the disease progressed such as diarrhea, vomiting and bleeding [1]. Initially, the
disease was thought to be one of the other viral hemorrhagic fevers known at the time,
such as Crimean Congo hemorrhagic fever or Marburg disease [2]. Indeed, initial
characterization by electron microscopy revealed particles similar in morphology to
Marburg virus (MARV) [3,4,5]. However, the virus isolated from the Yambuku outbreak
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was found to be serologically distinct from MARV and was given the name, Ebola virus,
after the nearby Ebola River [1].
It is interesting to note that almost concomitantly to this outbreak of what would
later be identified as the Zaire subtype of EBOV, an outbreak of a genetically distinct
subtype had begun just months earlier in Sudan. (The Sudan outbreak would be
investigated slightly after the Zaire outbreak, as a World Heath Organization team was
only dispatched to Sudan in late October of 1976 [6].) The Sudan outbreak occurred
primarily in the villages of Nzara and Maridi, only a few hundred kilometers northeast of
the Bumba region in Zaire (Figure 1-1). The approximately 4 day journey between Nzara,
Sudan and Bumba, Zaire was occasionally made by residents of that region, and so at the
time it was considered a possibility that an infected individual had traveled from Nzara to
the Yambuku hospital to initiate that outbreak [1,6]. Subsequent genetic analysis of the
viruses from these first two EBOV outbreaks confirmed their distinct phylogeny, thereby
disproving this theory; nevertheless, the temporal and geographic coincidences remain.
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Figure 1-1
Map of Sudan and Zaire EBOV outbreaks. Map shows the main sites
of the first two documented outbreaks of EBOV. Both outbreaks occurred during the fall
of 1976 and were separated by only several hundred kilometers, yet the species of virus
were genetically and serologically distinct.
Figure taken from: (1978) Ebola haemorrhagic fever in Sudan, 1976. Report of a
WHO/International Study Team. Bull World Health Organ 56: 247-270. Reprinted with
permission from the World Health Organization.
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1.2

Outbreaks and natural reservoirs
The Ebola virus is not known to be endemic to any human population, but instead

sporadically outbreaks. Since the first documented outbreaks in 1976, a total of 16
separate human outbreaks have occurred. Additionally, 5 additional human cases have
been reported which did not result in a wider outbreak [7,8,9,10]. In total, 2,292 human
cases of Ebola Hemorrhagic Fever (EHF) have been reported, resulting in 1,526 deaths.
Furthermore, 13 human cases of asymptomatic EBOV infection have been reported in
connection with outbreaks of the Reston subtype of EBOV in non-human primates or
swine. These individuals seroconverted but showed no other symptoms of EHF
[11,12,13].
Outbreaks of pathogenic EBOV in human populations have occurred exclusively
in the sub-Saharan African countries of Zaire (DRC), Sudan, Côte d'Ivoire, Republic of
Congo, Gabon and Uganda. Nonhuman primates, many species of which inhabit this
region, are also acutely susceptible to EBOV. Serological studies and genetic detection in
several central African primate species have revealed exposure to and infection with
EBOV in Cameroon, Gabon and Republic of Congo [14,15]. Additionally, the Reston
subtype of EBOV has caused disease outbreaks in the Philippines in nonhuman primates
and swine [13,16].
Although humans can transmit the virus to one another, they are considered nonnatural hosts for EBOV. There is no known insect vector that can transmit the virus.
Index cases are thought to occur through zoonotic events, either from a natural animal
reservoir or from an incidental animal host [17]. Human outbreaks in Gabon and the
4
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Republic of Congo have been epidemiologically linked to such intermediate hosts,
including chimpanzees, gorillas and forest duikers through the handling of infected
carcasses by local hunters [18,19]. However, because EBOV is highly pathogenic in
these animals, they are considered poor candidates for a natural reservoir for the virus. In
the Philippines, where two documented outbreaks of the Reston subtype of EBOV have
occurred, swine have been found to host the virus. Human exposure to this strain is
thought to have occurred though contact by farmers with pigs or their products. However,
it remains unknown whether swine are incidental hosts, or part of the natural replication
cycle of the virus [13].
Recently, several species of fruit bats have been implicated as being a natural
reservoir for EBOV [20,21,22]. The presence of EBOV-specific IgG or viral sequences
have be detected in six species: Micropteropus pusillus, Mops condylurus, Rousettus
aegyptiacus, Hypsignathus monstrosus, Epomops franqueti, and Myonycteris torquata,
although live virus has yet to be isolated from a bat [21,22]. Interestingly, the natural
habitat for several of these species encompasses the sub-Saharan region where EBOV
outbreaks have occurred (Figure 1-2). Fruit bats have also been directly implicated as the
source of a 2007 outbreak in the DRC [23]. EBOV may be non-pathogenic in these
animals and may replicate at very low levels. Virus could be transmitted from bats to
humans during hunting or from bats to forest animals through bodily fluids in droppings
or partially eaten fruit. Taken together, these data- though not conclusive- strongly
suggest that certain species of fruit bats may be a reservoir for EBOV.
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Figure 1-2
Habitat map of bats exposed to EBOV. Geographic distribution (inside
coloured lines) of the fruit bats Hypsignathus monstrosus (blue), Epomops franqueti (red)
and Myonycteris torquata (yellow).
Figure and legend taken from: Leroy EM, Kumulungui B, Pourrut X, Rouquet P,
Hassanin A, et al. (2005) Fruit bats as reservoirs of Ebola virus. Nature 438: 575-576.
Reprinted with permission from Nature Publishing Group.
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1.3

Epidemiology and clinical syndrome
After an initial transmission event from animals to people, the spread of infection

between individuals is dependent on close personal contact with infected bodily fluids.
Nosocomial transmission is common and was observed in the first documented outbreak
in Zaire, where poorly sterilized needles were used to give treatments to multiple patients
at the Yambuku Mission Hospital, likely causing several infections [1]. During outbreaks,
health care workers exposed to Ebola infected patients often became infected themselves,
presumably through poor barrier-nursing practices [1,6,24,25,26,27]. Transmission can
also occur when family members care for infected individuals at home, and also through
contact with cadavers during certain burial practices [24,25,27].
EBOV infection in humans is acute and fulminant. To date, five subtypes of
EBOV have been identified: Zaire, Sudan, Bundibugyo, Côte d'Ivoire, and Reston. Of
these, Zaire, Sudan, and Bundibugyo cause EHF that is fatal in ~30 to 90% of cases
(depending mostly on the subtype of virus in the outbreak) making EBOV a biosafety
level (BSL) 4 agent [28,29]. Cote d’Ivoire was associated with one nonfatal human
infection, and Reston is considered non-pathogenic in humans [7,11,12]. The average
incubation period is approximately 6 days; however, incubation may range from 2 to 21
days [30,31]. The clinical syndrome of EHF may be divided into two phases. The first
stage typically lasts about 1 week; during this time patients present with symptoms such
as fever, myalgia, anorexia, nausea, vomiting, abdominal pain, arthralgia, asthenia,
diarrhea, and back pain [1,31,32]. This first stage may also be characterized by
conjunctivitis, sore throat and a maculopapular rash. About 7 days after the onset of
7
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symptoms, patients often have the appearance of convalescence. Patients that will go on
to survive continue convalescence for several weeks, while terminal patients encounter
the latter stage, which last an average of 3 days [31]. This second stage of the disease
may be characterized by bleeding at skin puncture sites, mucosal sites such as the gums,
nose, eyes or in the stool; however, hemorrhaging is only observed in a subset of patients
and there are conflicting reports as to the correlation of hemorrhaging and a fatal outcome
[1,31,32]. Death often occurs with tachypnea and patients usually die in a state of shock
or coma [31,33]. The cause of death is thought to be from septic shock and multi-system
organ failure, though this has only been directly studied in nonhuman primate disease
models [34,35].

1.4

Disease pathogenesis
Our understanding of the pathogenesis of EBOV is derived mostly from

experimental infection of nonhuman primates, as in-depth human studies are difficult to
perform in the rural setting of most human EBOV outbreaks. Two pathogenesis models,
rhesus macaques and cynomolgus macaques are typically used [34,35,36]. Initially,
EBOV is thought to replicate in monocytes and dendritic cells, which are aberrantly
activated and show abnormal cytokine profiles [35,37,38,39]. From this early stage, two
important pathogenic mechanisms may originate. First, coagulopathy may be initiated by
the upregulation of tissue factor by infected monocytes and macrophages [40]. This may
lead to disseminated intravascular coagulation (DIC), which is observed during infection
and likely contributes to hemorrhage symptoms and multi-organ failure [1,40,41].
8
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Second, adaptive immune responses appear to be disrupted. Cells of lymphocytic origin,
which are not productively infected by EBOV, are nonetheless depleted during infection
by an incompletely understood mechanism of bystander apoptosis [35,42,43,44,45]. The
loss of T and B cells prevents an adaptive immune response against the virus and
correlates with fatal outcomes [42,43]. Conversely, survivors of EHF are often
distinguished by their ability to mount an adaptive response, as judged by the production
of EBOV-specific IgG antibodies [42,43,46]. Left unchecked by aberrant or absent
immune responses, EBOV replicates to high titers in the blood. Viremia has been
reported above 106 PFU per mL blood and as high as 1010 viral RNA copies per mL
[1,47]. Not surprisingly, higher viral titers correlate with a fatal outcome [46,47].
After initial replication in sentinel immune cells, the virus is then thought to
traffic back to the regional lymph nodes, where the virus may disseminate through the
blood to other tissues. EBOV can productively infect many organs, including the
gastrointestinal tract, liver, and kidneys [35,38]. Endothelial and epithelial cells also
become infected at later stages of disease [35,48].
Several viral proteins likely play a key role in EHF pathogenesis. EBOV encodes
two proteins (VP35 and VP24, described later) that are specific inhibitors of the
interferon response and have been shown be potent in dendritic cells [37,49,50,51]. A
potential role for the viral glycoprotein in pathogenesis is the focus of this dissertation
and will be discussed in detail in latter sections.

1.4

Treatment and Prevention
9
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There are no licensed vaccines or antivirals for the treatment or prevention of
EHF. During outbreaks in rural African settings, care is mostly supportive and includes
pain management and fluid replacement. To contain ongoing outbreaks, international
medial teams have found the education of local medical staff on barrier-nursing practices,
and the institution of safe burial practices to be highly effective [24,25,26]. The
administration of convalescent patient blood products has been used to treat EHF in an
outbreak and an isolated case with reported success [9,33]. However, such passive
immunotherapy is controversial, as other factors may have played a role in patient
recovery and primate models have been unable to reproduce this efficacy [52,53,54].
Recently, several therapies for EHF have shown promise in experimental models.
The administration of recombinant nematode anticoagulant protein c2 (rNAPc2) has been
demonstrated to prolong and increase survival in rhesus macaques given a lethal EBOV
challenge [55]. rNAPc2 presumably provides protection through its inhibition of the
coagulation cascade, reducing the coagulopathy observed in this model. Other studies
have shown initial therapeutic benefit from the administration of antisense
phosphorodiamidate morpholino oligomers (PMOs) and small interfering RNAs (siRNA)
against EBOV proteins, which presumably interfere with viral replication. PMOs directed
against the polymerase, VP35 and VP24 have shown some prophylactic protection in
rhesus macaques [56]. siRNAs directed against the viral polymerase were shown to
protect guinea pigs and siRNAs directed against the polymerase, VP35 and VP24 were
shown to protect macaques in pre- and post- exposure challenge models [57,58]. Postexposure protection has also been achieved in primate models using recombinant
10
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vesicular stomatitis virus (rVSV) encoding the EBOV glycoprotein [59]. Notably, rVSV
was administered to an individual in the post-exposure setting of a laboratory needle
stick. The patient did not develop EHF, though it has not been determined if they were
productively infected [60].
Although only in the early stages of development, protein-based and small
molecule inhibitors of EBOV entry and replication are currently being investigated for
use as antivirals [61,62,63,64].
Although no approved vaccine exists for the prevention of EBOV infection,
significant progress has been made using several vaccine platforms. Human
parainfluenza virus type 3, rVSV, DNA and/or replication-defective adenoviral vectors,
and virus like particles have all shown promise in protecting primates against a lethal
EBOV challenge in a pre-exposure setting [65,66,67,68,69,70]. Efficacy trials of these
candidate vaccines in humans will probably not be possible due to the sporadic nature
and remote location of EBOV outbreaks. Thus, FDA licensure will be dependent on
safety and efficacy demonstrations in two animal models, termed the ‘animal rule’ [71].

1.5

Genomic organization, viral proteins and virion structure
EBOV is a member of the family Filoviridae in the order Mononegavirales, and

so encodes its genome in single-stranded linear RNA in the negative orientation. The
genome is approximately 19 kb long, and encodes 7 open reading frames (ORFs) [29].
The different subtypes of EBOV are approximately 35-45% divergent at the nucleotide
level but are considered highly genomically stable over time [28,72]. The EBOV genome
11
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contains 3’ and 5’ (leader, trailer) extragenic sequences that can form secondary
structures and serve to initiate transcription and genome replication [73,74]. Individual
genes are separated by conserved transcriptional signals. Figure 1-3 (A) shows the
organization of ORFs and intragenic features of the EBOV genome.
The EBOV genome encodes 8 major gene products, 7 of which are incorporated
into viral particles. The viral genomic RNA is encapsulated in a ribonuclear protein
(RNP) complex (nucleocapsid) consisting of the nucleoprotein (NP), minor nucleoprotein
(VP30), VP35, and polymerase (L) protein [75]. This complex is then coated in a matrix
layer consisting of the major matrix protein (VP40) and minor matrix protein (VP24).
This is further enveloped by a lipid bilayer studded with the main viral glycoprotein (GP)
(Figure 1-3 B). The eighth viral protein is the major product of the GP ORF, but is a
smaller, secreted glycoprotein, sGP [76]. The full-length membrane-spanning form found
in the viral envelope, GP, originates from the addition of an extra adenosine residue in
the glycoprotein transcript by the polymerase during transcription [76]. During infection,
the ratio between sGP and GP transcripts is approximately 80% / 20% [77]. The
processing and function of the different glycoprotein forms are described in the following
sections.
EBOV particles are filamentous in shape but are often branched or in circular
confirmations; they have a diameter of approximately 80 nm and a variable length that
can exceed 1000 nm [78,79].

12
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A.

B.

Figure 1-3 EBOV genome organization and virion structure. (A) Genomic
organization of EBOV. Coding regions are shown in colored boxes. IR= intergenic
region. NP= nucleoprotein. GP= glycoprotein. L= large polymerase subunit. (B)
Structure of a filamentous EBOV particle. Genome is encapsulated by nucleocapsid
complex (NP, L, VP30 and VP35), which is encased by the matrix (VP40 and VP24),
which is surrounded by a lipid envelope studded with GP.
Figures taken from: (A) Sanchez A, Rollin PE (2005) Complete genome sequence of an
Ebola virus (Sudan species) responsible for a 2000 outbreak of human disease in Uganda.
Virus Res 113: 16-25. (B) Mahanty S, Bray M (2004) Pathogenesis of filoviral
haemorrhagic fevers. The Lancet Infectious Diseases 4: 487-498. Reprinted with
permission from Elsevier.
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1.7

Glycoprotein processing, function and structure
Transcription and translation of the glycoprotein gene gives rise to several major

and minor products during infection. The major product of transcription is the pre- sGP
transcript. This is translated into pre- sGP protein, which is then cleaved by furin into
sGP and a small C-terminal fragment, the Δ peptide [80]. However, during transcription
the viral polymerase occasionally adds an extra adenosine residue while reading through
an editing region of 7 uridine residues. The resulting -1 ORF reads through the remaining
portion of the gene and encodes for the membrane-bound form of the EBOV
glycoprotein, GP [76,77]. Similar editing by the polymerase into a -2 ORF produces a
small secreted glycoprotein product (ssGP); however, this product has not been
demonstrated in the context of EBOV infection [81].
The GP transcript is initially translated as a precursor (GP0), which is then cleaved
by furin in the Golgi into two subunits: a surface subunit, GP1, and a membrane-spanning
subunit, GP2 [82]. These subunits remain covalently connected through a single
intermolecular cysteine bond [83]. This heterodimer associates non-covalently with two
other heterodimers in a higher-order trimeric complex to produce the GP spike that
incorporates into budding virions [84]. Figure 1-4 (A) shows the domains and features of
GP. In addition to anchoring the glycoprotein to the membrane, GP2 houses the fusion
machinery, which allows the RNP complex to be delivered to the cytosol [85]. Fusion is
accomplished by the formation of a 6-helix bundle between the alpha-helical heptad
repeat (HR) 1 and 2 regions after an internal fusion loop becomes anchored in the host
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A.

B.

Figure 1-4
Feature map and structure of EBOV GP. (A) Domain schematic of GP.
Domains observed in the crystal structure are coloured and numbered according to the
description in the text. White and hash-marked regions designate crystallographically
disordered and construct-deleted regions, respectively. SP, signal peptide; I, GP1 base; II,
GP1 head; III, GP1 glycan cap; mucin, mucin-like domain; IFL, internal fusion loop;
HR1, heptad repeat 1; HR2, heptad repeat 2; MPER, membrane-proximal external region;
TM, transmembrane domain. Red Y-shaped symbols designate the predicted N-linked
glycosylation sites; those sites marked with an asterisk were mutated. (B) Model of the
fully glycosylated GP. N-linked bi-antennary complex-type glycans (Gal2Man3GlcNAc4)
were modelled onto the GP1 glycan-cap subdomain. Oligosaccharides are shown as
yellow space-filling spheres and for clarity; only those glycans belonging to the purple
monomer are labelled. Note that the glycans on N228 and N563 reside on the back of the
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purple monomer and are partly obscured. The glycans at N204 and N268 are found in
regions that are poorly ordered in the structure and as a result: their tentative locations are
shown as orange ovals. The C termini of the last ordered residues of GP1, to which
mucin-like domains are linked, are marked with ‘C’ (top of the chalice), and coloured
spheres (beige, pink and purple) outline the predicted positions of the mucin-like domains
attached in each of these regions. Surface residues previously identified to be critical for
viral entry, recessed in the chalice bowl and RBS, are coloured green. Fab KZ52 (grey)
recognizes a non-glycosylated, predominantly GP2-containing epitope at the base of the
chalice.
Figures and legends taken from: Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR,
et al. (2008) Structure of the Ebola virus glycoprotein bound to an antibody from a
human survivor. Nature 454: 177-182. Reprinted with permission from Nature Publishing
Group.
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membrane [86,87,88]. The GP1 subunit is responsible for mediating attachment and entry
of the virus. This subunit houses a putative receptor-binding domain (RBD), which binds
tightly to the surface of susceptible cells [89,90,91]. Interestingly, at the C-terminus of
GP1 there is a large, highly glycosylated domain, called the mucin domain. This domain
plays a role in entry and GP-mediated cytopathology, both of which are described in the
following sections.
Glycosylation is a prominent feature of GP and composes about half the mass of
GP1 [83,92]. The Zaire GP contains 17 predicted N-linked oligosaccharides, 8 of which
are located in the mucin domain. The mucin domain may contain up to 80 O-linked sites,
with at least 17 highly-predicted, clustered sites, which confer mucin-like properties to
this domain. The level of N- and O- linked glycosylation in the mucin domain is
maintained across the subtypes of EBOV, despite extremely low sequence conservation.
The composition and structure of the glycans found on GP have been studied by mass
spectrometry [93,94]. GP was found to contain bi-, tri-, and tetra-antennary branched Nlinked glycans bearing reduced amounts of galactose, some high-mannose residues, and
very low amounts of sialic acid compared to sGP. Although glycosylation is
heterogeneous, these analyses indicate that, in general, glycans on sGP undergo more
processing and modification than do those on GP. O-linked glycosylation in the mucin
domain of GP was also examined and found to be composed of mostly core 2
glycosylation structures, with variable amounts of sialic acid.
The molecular structure of GP was solved to 3.4 Å resolution by Lee and
colleagues (Figure 1-4 B) [95]. This crystallographic structure reveals that the three GP1
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subunits form a chalice-like globular structure. In the GP2 subunit, the fusion loop and
HR1 regions wrap around the outside of the globular GP1 domains, and are thought to
help stabilize the structure. The RBD sits on top of the base domain with residues critical
for binding facing up. Positioned on top of and blocking access to the RBD is a small
glycosylated domain, termed the glycan cap. The mucin domain, which was genetically
deleted for crystallography, extends up and away from the viral membrane and globular
GP domains. The entire trimeric complex is approximately 35 Å wide at the chalice base,
140 Å tall, and has a radius of approximately 125 Å from the center of the chalice to the
distal end of the mucin domain (Lee, J. and Saphire, E.O., unpublished data)

1.8

Viral entry
EBOV, like all viruses, is an obligate intracellular pathogen, and so must enter a

host cell to replicate. GP is the only viral protein found of the virion surface and so is
responsible for mediating entry and fusion of the virus. The first step of entry is
attachment. Because the mucin domain is the prominent feature on the virion surface, it
seems likely that initial attachment steps occur through interactions of this domain with
host cell surface factors. This hypothesis is supported by several studies, which have
demonstrated that C-type lectins such as DC-SIGN or L-SIGN enhance GP-mediated
entry through interactions with the mucin domain [96,97,98]. This is significant because
residues in the RBD that mediate binding to the cell surface are not exposed on fulllength GP, but buried under the glycan cap and mucin domains [95]. In the context of
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virus-like particles, the mucin domain has also been shown to induce intracellular
signaling in dendritic cells, which may aid in downstream entry or replication steps [99].
EBOV must traffic to a low pH compartment for fusion, however the mechanism
of endocytosis is poorly understood [100,101]. Clathrin has been implicated in the
endocytosis of EBOV, although the large size of EBOV particles would seem to exclude
this pathway [102]. Several signaling molecules, such as phosphoinositide-3 kinase, Rho
GTPases, and tyro3 family members have also been implicated in endocytic steps
[103,104,105]. Recent, but as yet unpublished studies have also implicated
macropinocytosis as an entry pathway [106,107].
The most well-characterized step in EBOV entry is the post-endocytic, pre-fusion
stage. After endocytosis, an EBOV-containing endosome matures into a late endosome
with a low pH, around 5.5. It is in this low pH compartment that resident endosomal
cathepsin proteases process GP1 into an activated form. Both cathepsin B and cathepsin L
have been shown to endoproteolitically cleave GP1, a process that is required for entry
[108]. Cathepsin processing takes place at residues 201 and 222, both of which are
located in a disordered and solution-exposed loop between the RBD and the glycan cap
[91,95,109]. This cleavage serves to remove the glycan cap and mucin domain from its
position over the RBD, potentially exposing the RBD for interactions with a receptor
(Figure 1-5) [91,95,110,111]. Studies describing these processing steps are further
supported by the fact that cathepsin processing of GP increases the binding and
infectivity of GP-bearing pseudovirions [110,111]. Interestingly, this cleaved GP, termed
primed GP, is still sensitive to inhibitors of cathepsins, suggesting that cathepsins are
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Figure 1-5
Structure of cathepsin processed GP. Receptor-binding residues
modeled on CatL-cleaved EBOV GP trimer structure. Left: Surface representation of the
ZEBOV-GP trimer structure (as reported in [95]) depicting N-glycan sites in the head
region (red) and residues important for virus entry (blue). GP1 is shown in shades of
orange and GP2 in shades of green. Right: The surface-modeled CatL-cleaved EBOV-GP
trimer structure (based on [95]) reveals the complete removal of all N-linked glycans
(red) from the head region surface and exposes the conserved core of the RBD and
critical residues for virus entry (blue).
Figure and legend minimally modified from: Hood CL, Abraham J, Boyington JC, Leung
K, Kwong PD, et al. Biochemical and structural characterization of cathepsin Lprocessed Ebola virus glycoprotein: implications for viral entry and immunogenicity. J
Virol 84: 2972-2982. Reprinted with permission from the American Society for
Microbiology. Structure based on: Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton
DR, et al. (2008) Structure of the Ebola virus glycoprotein bound to an antibody from a
human survivor. Nature 454: 177-182.
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required for a second step during entry [108,110]. Cathepsins could be additionally
required to act on a cellular receptor, or could further process GP after receptor-induced
structural rearrangements are triggered. After cathepsin processing, fusion occurs and the
contents of the viral particle are introduced into the cytoplasm.

1.9

Genome replication and viral budding
As with all RNA viruses with a negative sense genome, EBOV virus must

package its own RNA-dependent RNA polymerase (RDRP) so that it can initiate
transcription and replication. The L protein is the viral RDRP responsible for protein
transcription and full-length genome and anti-genome transcripts [73]. Transcription and
replication occurs in the cytoplasm where L works in complex with VP30, VP35 and NP
[112]. After transcription of the negative sense viral genome from a positive sense
intermediate, nacent genomes are packaged by nucleocapsid proteins.
Newly made RNP complexes must then associate with the matrix proteins for
packaging into budding particles. VP40 is the main matrix protein, which drives budding
at the plasma membrane and produces virus-like particles in the absence of other viral
proteins [113,114]. EBOV VP40 contains two overlapping late domains, which recruit
members of the endosomal sorting complexes required for transport (ESCRT) pathway
[115,116,117]. ESCRT complexes contain members of the vacuolar protein sorting
system, used by the cell to sort multivesicular body (MVB) cargo [118]. This same
machinery is usurped by the virus to create the membrane envagination necessary to bud
from the plasma membrane [117,119]. Lipid rafts at the plasma membrane may serve as
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the site of viral assembly and budding, as VP40 has been shown to target to these
microdomains [117,120]. Other potential sites of budding include MVBs and filopodia,
as have been proposed for MARV [121,122].

1.10

Glycoprotein-mediated cytopathology
In the past few decades, the use of recombinant DNA technology became a

common method to study individual viral gene products. The cloning of the EBOV GP
gene allowed the independent expression of GP in cells for the study of processes related
to this protein, such as viral entry. From these studies, a phenomenon was observed: GP
appeared to induce toxicity in cells in which it was expressed. This observation is the
focus of the studies described in this dissertation and is described in detail below.
EBOV GP expression, in the absence of other viral gene products, disrupts cell
adhesion causing a loss of cell-cell contacts and of attachment to the culture substrate,
resulting in rounded or floating cells [123,124,125]. This phenomenon is termed GPmediated cytopathology and is displayed in Figure 1-6. Such cytopathology can be
observed in a variety of cell lines, including human lines: 293T, 293H, HeLa, OV79,
HT1080, U87, and PMA-pretreated U937 cell; other mammalian lines: Vero, CCC, BHK,
and MC57 cells; and primary human cell types: umbilical vein endothelial, pulmonary
artery endothelial, coronary artery smooth muscle, cardiac microvascular endothelial, and
blood monocyte-derived macrophages (unpublished observations and [124,126]).
Interestingly, transient GP expression in the transformed human embryonic kidney cell
line, 293T, does not cause death, as these cells will regain their adhesive properties after
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Figure 1-6
EBOV GP-mediated cytopathology. EBOV GP transduction of cell lines
using adenovirus vectors. Adenovirus vectors (Ad) expressing avian sarcoma and
leukosis virus type A evelop (EnvA), Reston EBOV GP (EboR), or Zaire EBOV GP
(EboZ) were used to transduce a simian cell line, Vero (MOI, 10), a cat kidney cell line,
CCC (MOI, 10), or baby hamster kidney cells (BHK; MOI, 50). Cells were monitored at
regular intervals for evidence of cell rounding, and representative photographs were taken
at 48 h posttransduction. AGM, African green monkey.
Figure and legend minimally modified from: Simmons G, Wool-Lewis RJ, Baribaud F,
Netter RC, Bates P (2002) Ebola virus glycoproteins induce global surface protein downmodulation and loss of cell adherence. J Virol 76: 2518-2528. Reprinted with permission
from the American Society for Microbiology.
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GP expression wanes if maintained in culture [124]. In contrast, primary human cardiac
microvascular endothelial cells have been reported to undergo anoikis, or detachmentmediated apoptosis, upon transduction of GP [126].
The loss of cell adhesion associated with GP expression does not occur in trans,
meaning that in culture, non-expressing cells adjacent to a GP-expressing cell will not
undergo detachment. Similarly, when sGP or soluble, full-length, trimeric GP is secreted
from cells, neither these nor neighboring cells are affected [123]. This indicates that GP
must be expressed in a particular cell to induce cytopathology.
Because cell adhesion was so dramatically affected by GP, the integrin family
members were examined in several studies related to this topic. By flow cytometry, cells
expressing GP display significantly reduced surface levels of β1, α1, α2, α3, α4, α5 and
αV integrins [123,124,127]. Other surface proteins such as major histocompatibility
complex class I (MHC1) and platelet endothelial cell adhesion molecule 1 (PECAM-1)
are similarly effected; however, the exact complement of surface proteins affected by GP
appears to differ by cell type [124]. This apparent down-modulation of surface proteins,
in particular the various cell adhesion molecules (CAMs), provided an initial explanation
for the cell rounding phenotype.
The GPs from 4 of the 5 subtypes of EBOV (Zaire, Sudan, Côte d'Ivoire, and
Reston) have been examined for their ability to cause cytopathology. All 4 subtypes are
able to induce some degree of cell rounding, although Reston GP seems less able to do
so. Additionally, Reston GP induces only a modest down-modulation of surface integrins
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by flow cytometry [124]. Interestingly, MARV GP also contains a mucin domain, which
does not appear to cause cytopathology [128].
EBOV GP-mediated cytopathology is known to be dependent on the highly
glycosylated mucin domain within GP1. Constructs expressing GP with a genetic deletion
of this domain, GPΔmuc, do not cause cell rounding or detachment and do not show
down-modulation of surface proteins by flow cytometry [124,125,127]. Indeed,
sequential deletions of the mucin domain result in a progressive loss of cell detachment,
indicating the overall size or level of glycosylation of the domain is important for the
disruption of cell adhesion [124].
The role that GP-mediated cytopathology plays during viral pathogenesis is
largely unknown. It is important to note that EBOV infection of 293T cells was observed
to cause similar disruption of adhesion and a reduction of β1 and αV integrin and MHC1
staining by flow cytometry by 48 hours post infection, suggesting that observations from
transient GP expression are not simply artifacts of overexpression [129]. However, it has
been suggested that the balance between sGP and GP transcription, which produces
approximately 80% sGP and 20% GP, is a deliberate mechanism used by the virus to
limit GP cytopathology. To directly address this hypothesis, Volchkov and colleagues
used a reverse genetics system to rescue EBOV bearing an extra adenosine residue in the
GP gene RNA edit site [77]. This mutant virus produced significantly more GP and less
sGP and caused more cytopathic effects (CPE) in infected 293T cells than wt EBOV, for
which the authors report minimal CPE [77]. Because the extent of cytopathology may
differ between cell types, its effect on viral pathogenesis is difficult to gauge. In an initial
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study of GP-mediated cytopathology, the authors proposed that GP-induced loss of cellcell contacts could help explain the loss of vascular barrier integrity and resulting leakage
often seen during infection, though this remains controversial [48,125]. The disruption of
integrins and other CAMs such as PECAM-1 suggests that trafficking and diapedesis of
antigen presenting cells (APCs) could be disrupted upon infection [124]. Additionally,
the apparent down-modulation of β1 integrin was suggested to be indicative of its role in
viral entry, as viruses are known to down-modulate their receptors to aid in egress and
prevent superinfection; however, integrins have not been directly implicated as receptors
for the virus [123,130,131]. Additional mechanisms by which GP-mediated
cytopathology may contribute to pathogenesis are proposed in this dissertation and
discussed below.

1.11

Hypotheses addressed in this dissertation
The goal of this dissertation is to utilize cell biological and biochemical

techniques to explore the mechanism and consequences of GP-mediated cytopathology.
The domain requirements for GP had initially been investigated by our group and others.
As previously detailed, the mucin domain is a known requirement for the disruption of
adhesion and surface staining. However, it was not known whether the mucin domain
was also sufficient to induce cytopathology. This hypothesis is addressed in Chapter 2,
wherein we provide evidence that this domain is fully sufficient cause cytopathology. Of
critical focus in this dissertation is the cellular and molecular mechanism by which GPmediated cytopathology occurs. Before the present study was undertaken, there had been
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very few investigations into the mechanism by which Ebola GP disrupts adhesion and
causes surface protein down-modulation. Sullivan and colleagues had reported that this
process requires the cellular GTPase dynamin, which is an active regulator of several
endocytic pathways [127]. Additionally, it had also been reported that the extracellular
signal-regulated kinases (ERK 1/2) play a role in down-modulation, suggesting that
active signaling helped to drive these effects [132]. Therefore, we first undertook studies
to examine the role of dynamin in the process of cytopathology (also described in
Chapter 2) but found results that contrasted with Sullivan’s previous report. We then
developed a hypothesis based on the structure of GP and queried whether the heavilyglycosylated mucin domain of GP might be causing cytopathology by sterically
inhibiting the function of cell surface proteins. Chapter 3 details this study, which
supports a model of steric occlusion as the explanation for both the disruption of adhesion
and the appearance of surface protein down-modulation by flow cytometry. Interestingly,
we also found that GP could sterically shield its own epitopes from antibody recognition
at the cell surface, including a well-studied neutralizing epitope, bound by the KZ52
antibody.
We next wanted to address the potential consequences that GP-mediated
cytopathology might have on the immune response during virus infection. First, we
hypothesized that the occlusion of surface MHC1 molecules would have the functional
consequence of blocking antigen presentation to CD8 T cells, thereby preventing their
activation. We have found this to be the case, and have described these experiments in
Chapter 3. In Chapter 4, we explore the possibility that the heavily glycosylated domains
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within GP sterically affect access to virus. We hypothesize that steric occlusion of the
neutralizing epitope bound by the KZ52 antibody, occurs on viral particles and that this
may aid in the escape of neutralization. We have undertaken studies to identify the
domain in GP that occludes the KZ52 antibody. Furthermore, our experiments indicate
that steric occlusion does occur on viral particles; however, it remains unclear whether
this effect impacts virus neutralization.

1.12

Experimental approach
The following dissertation takes a reductionist approach to the study of the EBOV

by examining the interactions between GP and host cells. Such an approach has both
advantages and disadvantages. The justification for this approach is two-fold. First, the
low frequency and geographic seclusion of EBOV outbreaks make in-depth studies of
infected patients a near-impossibility. This has led to the characterization of several
animal models for studying EHF disease pathogenesis. Nevertheless, EBOV is a BSL 4
agent, adding significant cost and feasibility burdens to any live virus study. Therefore,
much of our understanding of the biology and biochemistry of the virus is accomplished
outside the context of viral infection for the sake of safety and feasibility. Second, it is
well appreciated that viruses are complex pathogens that interact with their hosts through
many pathways simultaneously. Viruses often encode functional redundancy, meaning
that more than one viral protein may function to accomplish a given task. One could think
of virus-cell interplay as a dense web of signals and interactions. Therefore, a reductionist
approach helps to simplify and focus the study of a single phenomenon in question.
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However, a reductionist approach also contains inherent caveats and drawbacks.
Functional redundancy could mean that important contributions to a certain phenomenon
from a supporting viral protein may be overlooked. Additionally, viruses also encode
functional ambiguity in their proteins, meaning that one viral protein may accomplish
multiple tasks. The latter is particularly well acknowledged for EBOV, whose genome is
relatively small and so whose proteins often interact with the cell in multiple ways. This
could introduce additional complexity into a given system; for example, GP may mediate
several functions within the cell through separate or intersecting pathways. These
limitations are well acknowledged, but it is judged here that the potential disadvantages
are outweighed by the opportunities presented by a reductionist approach.
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2.1

Abstract
The Ebola virus (EBOV) causes an acute hemorrhagic fever that is associated

with high morbidity and mortality. The viral glycoprotein is thought to play a significant
role in the pathogenesis of disease, though precise mechanisms are unknown. Cellular
pathogenesis can be modeled in vitro by the expression of the glycoprotein (GP) in cells,
which causes dramatic morphological changes, including cell rounding and surface
protein down-regulation. These effects are known to be dependent on the presence of a
highly glycosylated region of the glycoprotein, the mucin domain. Here we show that the
mucin domain from the highly pathogenic Zaire subtype of EBOV is sufficient to cause
characteristic cytopathology when expressed in the context of a foreign glycoprotein.
Similarly to full length Ebola GP, expression of the mucin domain causes rounding,
detachment from the extracellular matrix, and the down-regulation of cell surface levels
of β1 integrin and major histocompatibility complex class 1. These effects were not seen
when the mucin domain was expressed in the context of a glycophosphatidylinositol(GPI-) anchored isoform of the foreign glycoprotein. Moreover, cytopathology
associated with Ebola glycoprotein expression does not occur when GP expression is
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restricted to the endoplasmic reticulum. We also report that GP-induced surface protein
down-regulation is not mediated through a dynamin-dependent pathway, in contrast to a
previously published report.
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2.2

Introduction
The Ebola virus (EBOV) is a member of the family Filoviridae, and causes a

severe hemorrhagic fever in humans and non-human primates [1]. In cell culture, EBOV
infection causes pathogenic effects that result in destruction of the monolayer [2,3]. The
specific determinants of viral pathogenicity in vivo are still unknown; however, the viral
glycoproteins are thought to play a large role in cellular pathogenesis [4,5,6]. EBOV
encodes two forms of its glycoprotein, a dimeric secreted form (sGP) [7] and a trimeric
membrane-spanning form, GP, which originates from RNA editing of the glycoprotein
ORF [8]. No toxicity has been associated with sGP; however, because it is the
predominant form that is transcribed and translated, it is thought that the balance between
sGP and GP may be necessary to control the cytopathic effects attributed to GP [4,6].
When expressed in vitro and in vivo, GP causes cell rounding, detachment, and downregulation of many surface proteins, though cells are not immediately killed [4,9,10].
Among the surface proteins down-modulated by GP are β1 integrin (CD 29), α5 integrin,
αV integrin, and major histocompatibility complex class 1 (MHC1) in 293T cells [10].
However, the exact profile of protein down-regulation seems to differ by cell type. In
HUVEC cells, GP reduces surface expression of MHC1 and PECAM-1 but not β1
integrin [10].
Analysis of Ebola GP deletion mutants demonstrated that these morphological
changes, along with the down-regulation of surface proteins, are dependent on a highly
O- and N- glycosylated domain within GP, termed the mucin domain [4,9,10,11]. The
mucin domain is approximately 150 amino acids in length and is a conserved feature of
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filoviruses, though the primary sequence is highly variable among subtypes and strains.
The domain is thought to have little secondary or tertiary structure because of its high
level of glycosylation. Biochemical analysis has shown that after cleavage of the
glycoprotein precursor by furin [12] into GP1 (receptor-recognizing) and GP2 (membranespanning) fragments, the N-terminus of GP1 remains associated with GP2, leaving the
mucin domain exposed at the C-terminus of GP1 [13]. The mucin domain is not
necessary for GP surface expression or formation of infectious pseudotyped virions
[4,14,15]. There is no single region of the domain that contributes disproportionately to
the rounding phenotype, indicating that the phenotype may be dependent on the overall
size of the domain or level of its glycosylation [10].
Other viruses, such as the Bunyavirus, Crimean Congo Hemorrhagic Fever Virus
(CCHV) and the polydnavirus, Microplitis demolitor bracovirus (MdBV), encode
proteins with mucin-like domains. While no rounding or other cytopathology has been
reported for the CCHV mucin-like protein, the MdBV protein Glc1.8 causes rounding
when transfected into insect cells in a manner dependent on membrane association [16].
In addition, the cellular mucin protein MUC1 (episialin) has been shown to play a direct
role in the disruption of attachment factors such as β1 integrin when expressed in
melanoma and epithelial cell lines [17]. MUC1 is known to be highly and aberrantly
expressed in many adenocarcinomas and its expression correlates with increased
metastasis and poor prognosis [18,19,20]. MUC1 is thought to interfere with adhesion
through steric hindrance of necessary adhesion molecules [17]. In addition, it has been
shown that the size of the glycosylated region of MUC1 positively contributes to its
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ability to interfere with E-cadherin-based cell-cell interactions [21]. These data agree
with our previously-published study, which correlated the rounding phenotype to the size
of the EBOV GP mucin domain [10].
Although it has been well documented that the presence of the mucin domain is
necessary for GP-mediated cytopathology, it has yet to be shown that the mucin domain
is fully sufficient to induce the effects discussed above. One report found that murine
leukemia virus amphotropic envelope containing the mucin domain caused an increase in
floating cells in culture [4]. Here we analyzed the requirements for Ebola GP-mediated
cytopathology. We show that the mucin domain from the Zaire subtype of the EBOV
glycoprotein is sufficient to cause morphological alterations characteristic of GP
expression by placing it in the context of a heterologous, monomeric glycoprotein. Using
isoforms of this heterologous protein, we further demonstrate that a membrane-bound
form induces cytopathology, whereas a lipid- (GPI) anchored isoform does not. In
addition, very little is known about the mechanism of GP-induced cytopathology. Here
we show that cytopathology associated with the expression of GP does not occur when
GP is restricted to the endoplasmic reticulum (ER). It has also been reported that the
down-regulation of surface proteins by Ebola GP is likely mediated through a dynamindependent pathway [11]. However, data reported here support the alternative hypothesis
that this process occurs independently of dynamin.
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2.3

Materials and Methods

Plasmids, cell culture and transfections
Tva constructs were created by using two isoforms of the quail Tva ORF, Tva950
and Tva800 [22]. The transmembrane (Tva950) and GPI-anchored (Tva800) isoforms of
Tva used here have the accession numbers L22753 and L22752, respectively. For each
isoform, the mucin domain from the Zaire subtype (Mayinga strain) of the EBOV
glycoprotein (amino acids 312-462) or Reston subtype (amino acids 317-478) was cloned
between residues 77 and 78 of Tva. At the C-terminal end of the mucin domain, a flexible
three amino acid linker, AAV, or PAV was added just before Tva amino acid 78 for the
Zaire and Reston subtypes, respectively. To create an ER-retained version of Ebola GP,
cDNA encoding the membrane-anchored form of Ebola GP (Mayinga strain, accession
number U23187) was used. The four amino acid tag, KKMP, was appended to the Cterminus of the GP ORF. Constructs were cloned into the pCAGGS expression vector,
except where indicated. Amino acid positions stated here are counted from the initial
methionine. The dominant negative version of dynamin I (Dyn K44A) was a gift from
Sandra Schmid [23]. The coding region for Dyn K44A was removed from its original
vector by EcoRI and XbaI digest and cloned into a pcDNA3.1+ backbone to create a
mammalian expression vector.
All cells were cultured in DMEM (Gibco) with 10% bovine cosmic-calf serum
(HyClone) and penicillin/streptomycin (Gibco) at 37 ºC with 5% CO2. For flow
cytometry, fluorescence microscopy, and western blotting, 293T cells were plated at ~8 x
105 cells per well in 6-well plates one day prior to transfection. Cells were transiently
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transfected by calcium-phosphate precipitation with 6 µg DNA per well unless otherwise
stated. Cells to be visualized with GFP were co-transfected with an additional 2 µg
cDNA encoding eGFP. For enumeration of floating cells, 10 cm plates were plated with
4.5 x 106 293T cells one day prior to transfection; cells were transiently transfected with
30 µg DNA encoding GP or Tva constructs and 10 µg DNA encoding eCFP.
Immunofluorescence was performed using HeLa cells that were plated on glass
coverslips at 6 x 104 cells per coverslip in 24-well plates one day prior to transfection.
HeLa cells were transiently transfected by calcium-phosphate precipitation with 1.5 µg
DNA per coverslip. For all transfections, media was replaced 5 hours post-transfection.

Floating cell assay
24 hours after transfection, supernatants were removed and combined with 2 ml
PBS that had been used to gently wash the monolayer. An aliquot of the sample was
employed to determine cell concentration and total sample volume was measured. Only
CFP positive cells were counted using an improved Neubauer hemocytometer (Reichert)
on an Nikon TE300 inverted fluorescent microscope. Percent non-adherent cells were
calculated as: non-adherent cells / (adherent + non-adherent cells) x 100%. All
experiments were performed in triplicate.

Cell lysates and western blotting
Transfected cells were removed by resuspension in the culturing media. Cells
were pelleted at 4 ºC for 5 min at 1300 x g. Pellets were resuspended in RIPA buffer with
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complete protease inhibitor cocktail (Roche) for 5 minutes on ice or at room temperature.
Lysates were cleared by centrifugation at 4 ºC for 5 minutes at 20,800 x g. 30 µl samples
were mixed with reducing SDS buffer, boiled for 5 minutes, and separated on a 4-15%
Criterion PAGE gel (Bio-Rad). Proteins were transferred to PVDF (Millipore) at a 400
mA constant current. Membranes were blocked in 5% milk in TBS or 3% BSA in TBST
for 45 minutes or overnight. Membranes were probed with rabbit polyclonal anti-GP sera
[24], rabbit polyclonal anti-Tva sera [22], or mouse anti-dynamin I MAb (clone 41, BD
Transduction Labs) in blocking buffer. Protein was detected with stabilized goat antirabbit or anti-mouse HRP conjugated antibodies (Pierce) in blocking buffer for 45
minutes. Membranes were visualized with SuperSignal Femto substrate (Pierce).

Endoglycosidase assay
30 µl of each 293T cell lysate was incubated with denaturing buffer (NEB) for 10
minutes at 60 ºC. Samples were then incubated with buffer alone (G7 and NP40, NEB),
PNGase F, or Endo Hf plus appropriate buffers (NEB) for 4 to 6 hours at 37 ºC. Samples
were then separated by SDS-PAGE and blotted as described above.

Transferrin uptake assay
HeLa cells were plated at 1 x 105 cells per coverslip in a 24-well plate format.
Cells were transfected with Lipofectamine 2000 (Invitrogen) according to manufacturer’s
instructions with 1.5 µg per well of Dyn K44A or empty pcDNA3.1 vector. At 22 hrs
post transfection, media was removed and replaced with DMEM lacking serum. At 24 hrs
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post transfection, cells were placed on ice for 10 min. Human transferrin conjugated to
Alexa Fluor 594 (Invitrogen) was added to a final concentration of 100 µg/ml and
incubated on ice for 30 min. Cells were then washed 3 times with ice-cold PBS and either
immediately fixed (T=0) or incubated with DMEM + 10% serum at 37 ºC for 15, 30, or
60 min, then fixed. Cells were then stained for dynamin I as described later.

Flow cytometry
293T cells were detached from the TC plate 24 hours post transfection with PBS
-/-, 0.5 mM EDTA and combined with well media. Cells were pelleted at 4 ºC for 5 min
at 250 x g, then resuspended in wash buffer (PBS with 1% bovine calf serum and 0.05%
NaAzide) and aliquoted for staining. For detection of Ebola GP, cells were stained with
the human MAb, KZ52 [25] and detected with FITC anti-human IgG (PharMingen). For
detection of Tva proteins, cells were stained with rabbit polyclonal anti-Tva sera [22] and
detected with FITC goat anti-rabbit IgG (Rockland). For detection of β1-integrin, cells
were co-stained with anti-human CD29 PE-Cy5 conjugate (eBioscience); for detection of
MHC-1, cells were co-stained with anti- HLA-ABC PE-Cy5 conjugate (eBioscience).
For intracellular dynamin I staining, cells were permeabilized using Cytofix/Cytoperm
(BD Biosciences) for 20 min, followed by washing with Permwash (BD Biosciences).
For detection of dynamin I, cells were stained with mouse anti-dynamin Mab (clone 41,
BD Transduction Labs) and detected with anti-mouse Alexa Fluor 488 antibodies
(Invitrogen) in Permwash buffer. All staining was performed on ice for 1 hour, followed
by washing. Live cell gates were drawn based on forward and side scatter. For each
47

Chapter 2
sample, 10,000 events in the live cell gate were analyzed. Data were collected on a
Becton Dickinson FACSCalibur and analyzed using FlowJo software (Tree Star, Inc.).

Immunofluorescence microscopy
At 48 hours post-transfection, media was removed, cells were washed with PBS,
and fixed with 3% PFA in PBS for 20 minutes. Cells were then washed with PBS, then
permeabilized with 0.2% saponin, 1% goat serum in PBS for 5 minutes, then washed
with PBS. Cells were blocked with 10% goat serum, 0.1% Tween-20 in PBS for 2 hours.
For GP and ER staining, coverslips were incubated with mouse anti-Ebola GP MAb (gift
from Yoshihiro Kawaoka) and rabbit anti-calnexin (StressGen) and detected with goat
anti- mouse or rabbit Alexa Fluor 594 or 488 antibodies, respectively (Invitrogen). For
Golgi staining, cells were re-blocked with 10% mouse sera, then probed with mouse
MAb FITC anti-GM 130 (BD Transduction Labs). For Tva staining, coverslips were
incubated with rabbit polyclonal anti-Tva sera and detected with anti-rabbit Alexa Fluor
594 antibodies (Invitrogen). For dynamin I staining, coverslips were incubated with
mouse anti-dynamin I MAb (clone 41, BD Transduction Labs) and detected with antimouse Alexa Fluor 488 antibodies (Invitrogen). Cells were washed with PBS after each
staining step. For non-permeabilizing conditions, cells were fixed with 1% PFA in PBS
for 20 minutes, washed, then blocked with 10% goat serum in PBS and stained as
described above. All coverslips were mounted on glass slides with mounting medium
containing DAPI (Vectasheild). Z-section images were collected on a Leica DMRE
fluorescence microscope using Open Lab software (Improvision). Thirty z-sections per
48

Chapter 2
image were collected at 0.2 µm intervals. Z-section data were deconvoluted using
Velocity software (Improvision) to a 98% confidence level or 15 iterations. Images
shown are single, deconvoluted, z-sections except where indicated.
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2.4

Results

Characterization of Tva-mucin chimeric constructs
To investigate whether the mucin domain of Ebola GP was sufficient to cause cell
rounding and protein down-regulation, we created constructs in which the mucin domain
was placed into the heterologous, small monomeric glycoprotein, Tva. Tva is an avian
glycoprotein and is the cellular receptor for subgroup A avian sarcoma and leukosis virus
(ASLV) [22]. The quail Tva locus also produces a naturally-occurring splice variant that
associates with membranes through a GPI anchor instead of a transmembrane domain (P.
Bates, unpublished data), termed here, GPI Tva. The mucin domain from the Zaire
subtype of Ebola GP was cloned into vectors expressing both isoforms of Tva to create
expression plasmids for the proteins designated here as Tva-muc and GPI Tva-muc
(Figure 2-1 A). Analysis of lysates produced from 293T cells transfected with these
constructs demonstrated processing differences among the proteins (Figure 2-1 B). The
multiple bands within each lane represent glycosylation variants of the proteins while
differences between lanes reflect the transmembrane- verses GPI- anchored forms and the
added mucin domain. To investigate the cellular localization of these proteins,
immunofluorescence microscopy was performed on HeLa cells transfected with each
construct (Figure 2-1 C). Staining with a polyclonal antibody to a Tva peptide showed
both plasma membrane and cytoplasmic staining of each of the proteins. Expression of
the transmembrane-bound isoforms, Tva and Tva-muc exhibits a punctuate or vesicular
cytoplasmic staining, whereas GPI Tva and GPI Tva-muc show more of a reticular
cytoplasmic staining pattern. Addition of the mucin domain to either of the Tva isoforms
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Figure 2-1
EBOV GP-mucin domain is sufficient to induce cell rounding and
detachment. (A) Diagram of Tva constructs used to express Ebola Zaire GP-mucin
domain. Numbers indicate amino acid position starting from the initial methionine. (B)
239T cells were transfected with pCAGGS alone (vector) or pCAGGS encoding the Tva
constructs described in (A). Lysates were harvested in RIPA buffer after 24 h and
subjected to SDS-4 to 15% PAGE, transferred to PVDF, and immunoblotted with
polyclonal rabbit anti-Tva sera or GAPDH-specific monoclonal antibodies on blots run in
parallel. (C) HeLa cells were transfected with Tva constructs. 48 h posttransfection,
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cells were fixed, permeabilized, and stained for Tva with polyclonal rabbit anti-Tva sera
followed by Alexa 594 conjugated antibodies. Z-sections were captured on a
fluorescence microscope and deconvolved with software. Images shown are single,
deconvolved Z-sections. Scale bars are 10.6 µm. (D) 293T cells were co-transfected with
Tva constructs and a vector encoding eGFP in a 3:1 ratio. After 24 h fluorescent images
were captured on an inverted microscope using a GFP filter. Fields represent findings
from multiple experiments. (E) 239T cells were transfected with pCB6 vector alone or
pCB6 encoding the Tva constructs described in (A) and co-transfected with a vector
encoding eCFP in a 3:1 ratio. 24 h post-transfection, adherent and non-adherent cells
were removed. CFP positive cells were counted; data is shown as % non-adherent cells.
Graph shows mean of 3 replicates; error bars indicate SD. Results are representative of 2
independent experiments.
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did not cause any significant change in the observed staining patterns (Figure 2-1 C).

GP mucin domain is sufficient to cause GP-characteristic cytopathology
To address whether the expression of the chimeric mucin domain proteins could
induce similar morphological changes to those seen upon expression of EBOV GP, each
of the Tva constructs described above was mixed with an eGFP encoding vector and used
to transfect 293T cells. 24 hours after transfection, fluorescence microscopy was
performed to visualize transfected cells (Figure 2-1 D). While transfection of Tva or GPI
Tva did not induce any change in cell morphology, cells transfected with Tva-muc were
rounded and many had lost their ability to adhere to the extracellular matrix. In contrast,
the transfection of GPI Tva-muc had no effect on cell morphology. To quantify the
mucin domain-induced loss of adhesion to the extracellular matrix, 293T cells were cotransfected with the Tva constructs and an eCFP-encoding vector. Floating and adherent
cells were removed 24 hours post-transfection; only transfected (CFP positive) cells were
counted. Expression of Tva-muc caused cell detachment that was over ten-fold higher
than background levels (Figure 2-1 E). Transfection with Tva, GPI Tva, or GPI Tva-muc
did not result in cellular detachment significantly above background levels.
To further characterize the effects of the Ebola mucin domain on cellular
physiology, we used flow cytometry to measure surface levels of β1 integrin and MHC1
in transfected cells. Both of these proteins are known to be down-regulated from the
surface of cells expressing high levels of EBOV GP [9,10]. Cells that were transfected
with Tva showed no change in levels of β1 integrin or MHC1 after 24 hours; however,
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cells transfected with Tva-muc showed a roughly one log decrease in fluorescence of
both proteins (Figure 2-2). Close inspection of the FACS plots reveals that cells with low
expression of Tva-muc have intact levels of β1 integrin and MHC1; however, there
seems to be a threshold of Tva-muc expression, above which β1 integrin and MHC1
levels drop precipitously. By contrast, this threshold effect is not seen with GPI Tvamuc. The GPI Tva-muc sample has expression levels of the chimeric protein that would
be predicted to cause down-regulation of β1 integrin and MHC1, yet this is not observed.
From these results we conclude that the mucin domain of Ebola GP, when expressed
within the context of a transmembrane-bound form of Tva, is sufficient to cause
cytopathology characteristic of full-length GP expression.
To address whether mucin domains of different subtypes of EBOV differ in their
ability to cause cytopathology, we compared the mucin regions from Ebola Zaire to
Ebola Reston. Reston is considered to be the least pathogenic subtype of Ebola, while
Zaire is the most pathogenic [26]. The mucin domain of Ebola Reston was expressed
within the transmembrane-bound form of Tva. Interestingly, 293T cells that were
transfected with Tva-muc of the Reston and Zaire subtypes both showed equal reduction
of β1 integrin and MHC1 surface staining after 24 hours by flow cytometry (data not
shown).

Characterization of GP-kk
To address whether GP could exert its effects from the endoplasmic
reticulum or if transport to the cell surface is required, we created a version of the Ebola
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Figure 2-2
Surface protein down-regulation by EBOV GP mucin domain. 239T
cells were transfected with vector alone or vector encoding the Tva constructs described
in Figure 2-1 A. Floating and adherent cells were harvested 24 h after transfection,
pooled, and stained with polyclonal rabbit anti-Tva sera and FITC-labeled secondary
antibodies, co-stained for β1 integrin or MHC1 with PE-Cy5 conjugated monoclonal
antibodies and assayed by flow cytometry. Analysis is shown for events in the live cell
gate. (A) β1 integrin vs. Tva surface expression. (B) MHC1 vs. Tva surface expression.
(C) Histogram representation of β1 integrin surface expression (left panels) and MHC1
surface expression (right panels). Control samples are shown shaded; Tva or GPI Tva is
shown as a dashed line; Tva-muc or GPI Tva-muc is shown as a solid line. Data is
representative of multiple independent experiments.

55

Chapter 2
GP with an ER retention signal, KKMP, appended to the cytoplasmic tail of the protein
(GP-kk). Analysis of lysates made from 293T cells transfected with GP and GP-kk
demonstrated that the constructs were expressed to a similar level (Figure 2-3 A). To
characterize the glycosylation state of GP-kk, lysates from GP or GP-kk transfected cells
were incubated with PNGase F, which removes all N-linked glycans, and Endo Hf, which
removes high-mannose glycans, characteristic of proteins that have not matured through
the Golgi (Figure 2-3 B). When incubated with Endo Hf, the majority of GP-kk protein
co-migrates with PNGase F digested protein on SDS-PAGE. This Endo Hf sensitivity
suggests that GP-kk is not transported to the Golgi and remains in the ER. By
comparison, the majority of GP is resistant to Endo Hf digestion, as would be expected of
protein that has matured through the Golgi.

GP cellular localization
To further examine the localization of GP-kk, immunofluorescence microscopy
was performed on HeLa cells transfected with GP and GP-kk (Figure 2-3 C).
Permeabilized and non-permeabilized cells were stained with a monoclonal antibody to
Ebola GP and co-stained with an antibody to GM-130, a cis-Golgi localized scaffold
protein, to test the integrity of the plasma membrane during staining (Figure 2-3 C, top
and middle panels). GP-transfected cells displayed intense plasma membrane staining in
both permeabilized and non-permeabilized cells. Some internal vesicular staining was
noted for GP, however this showed no significant colocalization with GM-130 (Figure 2-
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Figure 2-3
EBOV GP does not round cells when restricted to the ER. (A) 293T
cells were transfected with vector alone, vector encoding for GP, or GP-kk (ERrestricted). Lysates were harvested in RIPA buffer after 24 h and subjected to SDS-4 to
15% PAGE, transferred to PVDF, and immunoblotted with polyclonal rabbit anti-GP sera
and GAPDH-specific monoclonal antibodies. (B) GP and GP-kk lysates were denatured
and incubated with enzyme buffer alone or buffer with PNGase F or Endoglycosidase Hf
(at normal or 3x concentration), then subjected to SDS-PAGE and immunoblotting as
described in (A). (C) HeLa cells were transfected with GP or GP-kk. 48 h
posttransfection, cells were fixed, either not permeabilized (top row) or permeabilized
(middle and bottom rows) and stained for GP with mouse monoclonal antibodies,
followed by Alexa 594 conjugated antibodies (red). Cells were also co-stained with
FITC-conjugated monoclonal antibodies to GM 130 (green) or with rabbit polyclonal
antibodies to calnexin, followed by Alexa 488 antibodies (green). Z-sections were
captured on a fluorescence microscope and deconvoluted. Images shown in top and
middle rows are composite, deconvoluted Z-sections. Images in the bottom row are
single, deconvoluted Z-sections; the merge panel also shows views in the XZ and YZ
planes. Scale bars are 10.6 µm. (D) 293T cells were transfected with vector alone, or
vector encoding GP, or GP-kk and co-transfected with eGFP in a 3:1 ratio. After 24 h
fluorescent images were captured on an inverted microscope using a GFP filter. Fields
represent findings from multiple experiments. (E) 293T cells were transfected with
vector alone or vector encoding for GP or GP-kk and co-transfected with a vector
encoding eCFP in a 3:1 ratio. 24 h post-transfection, adherent and non-adherent cells
were removed. CFP positive cells were counted; data is shown as % non-adherent cells.
Graph shows mean of 3 replicates; error bars indicate SD. Results are representative of 2
independent experiments.
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3 C, middle panels). By contrast, only very few non-permeabilized cells transfected with
GP-kk showed any surface staining (data not shown). For the majority of GP-kk
expressing cells, GP staining could only be seen upon permeablization (Figure 2-3 C,
bottom panels). Staining of these cells revealed a cytoplasmic, reticular pattern. GP-kk
appeared to co-localize with staining of the ER-resident protein, calnexin, but did not
demonstrate detectable colocalization with GM-130 (data not shown). Thus, we
conclude that GP-kk is actively retained in the ER through its retention signal.

GP-kk does not cause cytopathology
We then asked whether retaining Ebola GP in the ER had any effect on cell
rounding and protein down-regulation. 293T cells were transfected with GP, GP-kk, or
the empty vector and co-transfected with eGFP as above. 24 hours after transfection,
microscopy was performed using a GFP filter so that only transfected cells were
visualized (Figure 2-3 D). Cells transfected with the vector were flat and adherent,
whereas GP transfected cells were rounded and floating. Cells that had been transfected
with GP-kk were morphologically indistinguishable from the vector control. To quantify
this result, floating and adherent cells in culture dishes were counted 24 hours after cotransfection of the GP constructs with an eCFP-encoding vector (Figure 2-3 E). The
addition of the ER retention signal to GP resulted in a reduction the number of floating
cells by approximately 98%, to background levels. 293T cells transfected with GP or
GP-kk were stained with antibodies to Ebola GP and β1 integrin or MHC1 and analyzed
by flow cytometry. Whereas GP strongly down-regulated β1 integrin and MHC1, GP-kk
59

Chapter 2
did not (Figure 2-4). Flow cytometric analysis of GP-kk transfected cells, surfaced
stained for Ebola GP, reveals that a small percentage of transfected cells express GP-kk
on the surface, despite the ER retention signal (Figure 2-4). This observation is
supported by immunofluorescence microscopy studies, where some surface-stained cells
are observed, and also endoglycosidase assay data (Figure 2-3 B), in which a small
amount of Endo Hf-resistant protein in the GP-kk sample is visible. Interestingly, in the
small amount of cells that show some surface staining for GP-kk, levels of β1 integrin
and MHC1 do not appear altered. It should also be noted that GP-transfected cells show
down-regulation of GP from the surface resulting in comma-shaped FACS plots (Figure
2-4 A, B). However, this comma-shaped profile was not observed with the Tva
constructs (Figure 2-2 A, B). These data allow us to conclude that the Ebola GP does not
cause morphological changes and protein down-regulation when retained in the ER.

Surface protein down-regulation is not mediated through a dynamin-dependent
pathway
To address whether surface protein down-regulation was affected by the
expression of a dominant-negative version of dynamin as previously reported [11], we
employed a construct expressing human dynamin I with a K44A mutation (Dyn K44A).
This mutation is known to disrupt coated vesicle formation and trafficking by exerting a
dominant negative effect on dynamin’s role in vesicle formation [23]. Analysis of lysates
made from 293T cells transfected with Dyn K44A demonstrated that the construct was
expressed and that the dynamin I antibody specifically recognized the transfected
dynamin I protein, not endogenous dynamin II (Figure 2-5 A). To examine the ability of
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Figure 2-4
EBOV GP does not induce surface protein down-regulation when
restricted to ER. 293T cells were transfected with vector alone or vector encoding GP
or GP-kk. Floating and adherent cells were harvested 24 h after transfection, pooled, and
stained with antibodies to GP using human monoclonal antibodies and FITC-labeled
secondary antibodies, co-stained for β1 integrin or MHC1 with PE-Cy5 conjugated
monoclonal antibodies and assayed by flow cytometry. Analysis is shown for events in
the live cell gate. (A) β1 integrin vs. GP surface expression. (B) MHC1 vs. GP surface
expression. (C) Histogram representation of GP surface expression (left panel), β1
surface expression (middle panel), and MHC1 surface expression (right panel). Control
samples are shown shaded; GP is shown as a solid line, and GP-kk is shown as a dashed
line. Data are representative of multiple independent experiments.
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Dyn K44A to block vesicle trafficking, a transferrin uptake assay was performed. As
shown in Figure 2-5 B, labeled transferrin bound the surface of HeLa cells at 4 ºC. When
incubated at 37 ºC for 15 min., cells internalized the transferrin; however, transferrin
remained at the surface of cells transfected with Dyn K44A. This effect was also seen
after incubation for 30 min.; after 60 min. the transferrin was mostly degraded (data not
shown). Thus, our Dyn K44A behaves as a functional dominant negative of dynamindependent pathways.
We then addressed whether the expression of Dyn K44A would alter the level of
surface protein down-regulation in GP-transfected cells. Transfection of Dyn K44A alone
did not alter the surface levels of β1 integrin or MHC1 (data not shown). However,
Sullivan et. al reported that transfection of dominant negative dynamin reduced nearly
half of the down-regulation of αV integrin and a significant portion of the downregulation of MHC1 by GP [11]. In contrast, we found that after co-transfection of DNA
encoding Dyn K44A and GP in a ratio of 3:1, no change in the down-regulation of
MHC1 or β1 integrin could be observed (Figure 2-5 C). It should be noted that the
transfection efficiency of GP in these experiments varied by less than 2% between
samples (Figure 2-5 C, upper left-hand quadrants). We also examined the effect of Dyn
K44A on the down-regulation of β1 integrin and MHC1 by Tva-muc. Transfections were
performed as with GP. Our data indicate that Dyn K44A does not reduce the number of
cells in Tva-muc transfected cultures that have down-regulated levels of β1 integrin and
MHC1 (Figure 2-5 D).
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We have previously reported that in cultures transfected with GP, floating cells
are 90% positive for GP expression and 95% viable [10]. Here we demonstrate that
floating cells also exhibited the most dramatic phenotype of surface protein downregulation (Figure 2-5 E). To ensure that cells co-transfected with GP and Dyn K44A
expressed Dyn K44A, floating cells were also analyzed by intracellular staining for
dynamin I. Flow cytometry revealed that 95% of floating cells stained positive for
dynamin I (Figure 2-5 F).
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Figure 2-5
GP-mediated surface protein down-regulation is not mediated by
dynamin I. (A) 293T cells were transfected with vector alone or vector encoding
dynamin I K44A (Dyn K44A). Lysates were harvested in RIPA buffer after 24 h and
subjected to SDS-4 to 15% PAGE, transferred to PVDF, and immunoblotted with antidynamin I mouse MAb. (B) HeLa cells were transfected with Dyn K44A. After 22
hours, cells were serum starved for 2 hours. Cells were then iced and incubated with
Alexa 594-conjugated human transferrin. Cells were either immediately fixed (T=0), or
incubated at 37ºC for 15 minutes (T=15). Cells were fixed, permeabilized, and stained
for dynamin I as described in Materials and Methods, then analyzed by fluorescent
microscopy. (C, D) 293T cells were co-transfected (in a 1:3 ratio) with GP and vector or
GP and Dyn K44A (C), Tva-muc and vector or Tva-muc and Dyn K44A (D). Floating
and adherent cells were harvested 24 h after transfection, pooled, and stained with
antibodies to GP using human monoclonal antibodies and antibodies to Tva using a
polyclonal rabbit anti-Tva sera followed by FITC-labeled secondary antibodies, costained for β1 integrin or MHC1 with PE-Cy5 conjugated monoclonal antibodies, and
assayed by flow cytometry. (E) 239T cells were transfected with GP. After 24 hours,
floating cells were either pooled with adherent cells (left plot) or separated from adherent
cells (right plot) and stained for GP and β1 integrin as described previously. (F) 293T
cells were co-transfected with GP and Dyn K44A (black line) in a 1:3 ratio. Floating cells
were harvested after 24 hours, permeabilized, and stained for intracellular dynamin I.
Shaded peak represents GP + vector-transfected cells stained for dynamin I. Analyses are
shown for events in the live cell gate. Data are representative of multiple independent
experiments.
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2.5

Discussion
The mucin domain of Ebola GP seems to have no critical function in entry or

fusion of Ebola pseudotypes, but instead decreases the efficiency of in vitro pseudotype
infection [14,15]. However, selective pressure to maintain this domain and conserve its
length and glycosylation suggests that this portion of the viral glycoprotein plays an
important role in other aspects of the viral infection cycle in vivo. Because of its
placement within the glycoprotein trimer, the mucin domain is in a position to interact
with other cellular surface proteins or protect the rest of GP from immune recognition. In
fact, Takada and colleagues have shown that the mucin domain is important for
interactions with certain C-type lectins and suggest that these interactions may play a role
in virus entry [27]. Such interactions may also be the basis for the cytopathic effects
discussed here.
A recent report by Alazard-Dany et al. demonstrated that moderate to low levels
of GP expression do not induce cell rounding [2]; this is in agreement with our data,
which indicates that 293T cells down-regulate surface proteins after reaching a threshold
of surface GP expression (Figure 2-4 A, B). Data from Alazard-Dany et al. also
demonstrate that cell rounding, detachment, and the down-regulation of β1 integrin and
MHC1 can be observed by 48 hours post-infection with EBOV, suggesting that this effect
is not an artifact of over-expressing GP in vitro.
The data presented here demonstrate that the mucin domain of Ebola Zaire is
sufficient to cause cytopathic effects that are comparable with those caused by full-length
Ebola GP. Tva-muc induces cell rounding and detachment in 293T cells and significant
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surface down-regulation of both β1 integrin and MHC1. The extent to which this cellular
phenomenon contributes to viral pathogenesis remains to be tested; however,
cytopathology may have several effects. Non-human primate studies have revealed that
the innate immune response and resulting communication of antigen-presenting cells
(APCs) to the adaptive arm of the immune system is disrupted during Ebola infection
(reviewed in [28]). Therefore, effects of GP-mediated cytopathology on APCs could
contribute to immune dysregulation. Because integrins are known to play a critical role in
the homing of leukocytes to sites of infection [29], loss of adhesion may disrupt the
function of macrophages or dendritic cells; we have shown GP expression to cause
rounding in macrophages [10]. The down-regulation of MHC1 in other cell types could
be a mechanism of escape from CD8+ T-cell surveillance. Additionally, loss of adhesion
by GP transduction in cultured saphenous veins is thought to be a model for hemorrhagic
symptoms seen during Ebola infection [4,11]. Finally, loss of adhesion by Ebola GP has
been shown to cause anoikis in primary endothelial cells [30]. GP-induced loss of
adhesion and resulting anoikis could provide one mechanism for necrosis seen during
infection, specifically in organs such as the liver where immune infiltration is limited;
other cellular factors such as tumor necrosis factor-related apoptosis-inducing ligand have
also been implicated [31,32].
If the effects of the mucin domain contribute to the pathogenesis of the Zaire
subtype of EBOV, one might expect cytopathology caused by the less-pathogenic Reston
subtype to be measurably less. Indeed, our previous report comparing Ebola GP Zaire
and Reston found that GP Reston caused fewer floating cells in culture and less loss of
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surface staining of integrins and MHC1 by flow cytometry [10]. Interestingly, our
comparison of the mucin domains from the Ebola subtypes Reston and Zaire indicate that
both are equal in their ability to cause cytopathology from the Tva platform. This
suggests that the presentation of the mucin domain the context of the full glycoprotein
may affect the ability of the domain to cause cytopathology. It is also interesting that,
while the mucin domain normally induces the rounding phenotype from within the GP
trimer, we have demonstrated that it is able to exert these effects from within the
monomeric protein, Tva.
When the mucin domain of GP is expressed in the context of the GPI-anchored
isoform of Tva, the rounding phenotype is abolished and protein down-regulation of
MHC1 and β1 integrin is not observed. It is possible that the mucin domain in GPI Tvamuc is physically positioned or becomes differentially glycosylated in such a way that
prevents rounding. A more appealing alternative is that GPI Tva traffics or is localized at
the plasma membrane differently than Tva. Immunofluorescence microscopy analysis of
these constructs in HeLa cells shows possible differences in internal staining, but does
not reveal any discernable difference in plasma membrane staining (Figure 2-1 C).
However, it has been reported that GPI Tva localizes to detergent-resistant membranes,
while Tva does not, and that GPI Tva traffics to an acidic compartment through a
different endocytic pathway than Tva upon binding of ASLV [33]. These characteristics
could explain the differences between Tva-muc and GPI Tva-muc. It is also probable
that the addition of the Ebola mucin domain further affects the membrane localization or
trafficking pathways used by Tva.
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The mechanism by which Ebola GP causes cytopathology is also unknown. A
recent report provides evidence that GP utilizes a dynamin-dependent pathway to cause
surface protein down-regulation [11]. Dynamin has been implicated in vesicle fission for
several pathways, including clathrin- dependent and independent endocytosis, as well as
trans-Golgi budding [34,35,36]. Therefore, it is possible that GP alters surface protein
levels by affecting endocytosis. We addressed the function of dynamin in the process of
GP- and Tva-muc- mediated surface protein down-regulation. As demonstrated in Figure
2-5, a dominant negative version of dynamin I was able to block the endocytosis of the
transferrin receptor, but could not block the down-regulation of β1 integrin or MHC1 by
GP or Tva-muc. Thus, we propose a model of down-regulation that is independent of
dynamin-regulated pathways.
The two surface proteins studied here, β1 integrin and MHC1, both undergo
constant endocytosis and recycling back to the plasma membrane [37,38,39,40]. Many
viruses encode proteins that modulate MHC1 levels at the cell surface. For example, the
K3 and K5 proteins from Kaposi's sarcoma-associated herpesvirus increase the rate of
MHC1 endocytosis [41]. Other viruses block MHC1 expression by interfering in the ER.
The US11 gene encoded by the human cytomegalovirus retro-translocates newly
synthesized MHC1 molecules out of the ER where they are degraded by the proteosome
[42]. Furthermore, some viral proteins are able to modulate MHC1 levels by influencing
multiple pathways. The Nef protein from HIV has been reported to increase endocytosis
of MHC1 and also to redirect newly-sythesized MHC1 from the trans-Golgi network
(TGN) to the lysosome [43,44,45]. Therefore, it seemed prudent to ask whether Ebola
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GP could cause rounding and protein down-regulation when restricted to the ER. As
shown in Figures 2-3 and 2-4, our findings reject a model of down-regulation of β1
integrin and MHC1 by interference in the ER. These data suggest a mechanism of
regulation at the plasma membrane or TGN.
GP directs the down-regulation of surface proteins, but also appears to downregulate its own surface expression in a manner that seems concurrent with that of β1
integrin and MHC1 (Figure 2-4 A, B). Because the mechanism of action is unknown, it
is not clear if GP plays a direct role in guiding the down-regulation of other surface
molecules. It has, however, been reported that GP and αV integrin, which is also downregulated in 293T cells, can be co-immunoprecipitated [11]. If GP directly binds to
proteins to facilitate down-regulation, this could explain the observation that cells
showing down-modulation of β1 integrin or MHC1 have reduced surface levels of GP
(Figure 2-4). Interestingly, Tva-muc is able to down-regulate β1 integrin and MHC1
without a reduction in surface expression of Tva-muc (Figure 2-2 A, B). This could
indicate that the mechanism of down-regulation is indirect, such as through a signaling
cascade which affects endocytosis and/or recycling. Alternatively, it is possible that Tvamuc interacts directly with β1 integrin and MHC1, but simply recycles back to the
plasma membrane more efficiently than GP.
When GP-kk is expressed in 293T and HeLa cells, a portion of cells show some
expression on the surface despite the ER retention motif (Figure 2-4 C). It is unclear
whether this is the result of cleavage of the KK signal off of the C-terminus, or
overwhelming of the ER retention machinery due to over-expression. Interestingly, cells
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that do express GP-kk on the surface do not round or detach and show no downregulation of β1 integrin or MHC1. FACS analysis (Figure 2-4 C, left panel) shows that
surface-localized GP-kk is expressed at a much lower level than GP. In addition, analysis
of GP down-regulation seems to indicate that GP reaches a critical density on the surface
before down-regulation occurs (Figure 2-4 A, B). Thus, it is possible that in the cells
where GP-kk is expressed on the surface, the glycoprotein does not reach the required
density and therefore does not induce protein down-regulation. Although the precise
mechanism of GP-mediated cytopathology remains unknown, the mucin domain of GP
has the ability to play an important role in the pathogenesis of EBOV. Cellular loss of
adhesion by the mucin domain of GP may contribute to hemorrhagic symptoms, and in
combination with reduction in levels of immune regulatory proteins such as MHC1, is
likely a critical part of the strategy for immune evasion by EBOV. In this regard it will
be interesting to analyze the effects of the mucin domain in cells derived from the natural
hosts for Ebola.
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3.1

Abstract
Many viruses alter expression of proteins on the surface of infected cells

including molecules important for immune recognition, such as the major
histocompatibility complex (MHC) class I and II molecules. Virus induced downregulation of surface proteins has been observed to occur by a variety of mechanisms
including impaired transcription, blocks to synthesis, and increased turnover. Viral
infection or transient expression of the Ebola viral glycoprotein (GP) was previously
shown to result in loss of staining of various host cell surface proteins including MHC1
and β1 integrin, however the mechanism responsible for this effect has not been
delineated. In the present study we demonstrate that Ebola GP does not decrease surface
levels of β1 integrin or MHC1, but rather impedes recognition by steric occlusion of
these proteins on the cell surface. Furthermore, steric occlusion also occurs for epitopes
on the Ebola glycoprotein itself. The occluded epitopes in host proteins and Ebola GP
can be revealed by removal of the surface subunit of GP or by removal of surface N- and
O- linked glycans, resulting in increased surface staining by flow cytometry. Importantly,
expression of Ebola GP impairs CD8 T cell recognition of MHC1 on antigen presenting
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cells. Glycan-mediated steric shielding of surface proteins by Ebola GP represents a
novel mechanism for a virus to affect host cell function and escape immune detection.

77

Chapter 3
3.2

Introduction
The Ebola virus (EBOV) is an enveloped, negative-stranded RNA virus, a

member of the family Filoviridae, and the causative agent of Ebola hemorrhagic fever.
To date, five subtypes of EBOV have been identified: Zaire, Sudan, Côte d'Ivoire, Reston
and Bundibugyo. Zaire is the most pathogenic subtype in humans, with mortality rates
reaching 90% [1]. The basis for the high pathogenicity of EBOV is unclear, however
immune dysregulation has been hypothesized to play a role [2]. Similarly to many other
viral systems, EBOV infection appears to down-modulate the expression of host surface
proteins involved in cellular recognition, most notably major histocompatibility complex
(MHC) molecules and integrins [3].
EBOV encodes two forms of its glycoprotein. One is a dimeric, secreted form
(sGP), which is transcribed directly from the viral RNA [4,5] and whose function remains
unclear. A second glycoprotein species results from transcriptional editing of the
glycoprotein ORF and encodes a trimeric, membrane-bound form (GP). This form is
expressed at the cell surface and is incorporated into the virion [4] and drives viral
attachment and membrane fusion. GP is initially translated as a precursor (GP0), which is
then cleaved by furin in the Golgi into two subunits, a surface subunit, GP1 and a
membrane-spanning subunit, GP2 [6]. These subunits remain covalently connected
through a single intermolecular cysteine bond [7]. Expression of the main viral
glycoprotein, GP, has been shown to cause effects in cell culture on host surface proteins
similar to those observed during viral infection, and so is proposed to be an important
determinant of viral pathogenesis [8,9,10,11]. Because sGP is the predominant form
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transcribed, it has been postulated that the balance between sGP and GP serves to
regulate the effects of GP [11].
EBOV GP expression in cultured cells disrupts cell adhesion resulting in loss of
cell-cell contacts as well as cell rounding and loss of attachment to the culture substrate
[8,10,12]. This can be observed in a variety of cell lines and primary cell types [12].
Interestingly, while transient GP expression does not cause death in human embryonic
kidney 293T cells, primary human cardiac microvascular endothelial cells have been
reported to undergo anoikis, or detachment-mediated apoptosis, upon transduction of GP
[12,13]. By flow cytometry, cells expressing GP display dramatically lowered levels of
various surface proteins, including several members of the integrin family and MHC
class I (MHC1); however, the exact complement of surface proteins affected by GP
appears to differ by cell type [10,12,14]. Importantly, EBOV infection of 293T cells was
observed to cause similar reduction of β1 integrin and MHC1 staining by flow cytometry,
suggesting that observations from transient GP expression are not simply artifacts of
overexpression [3]. The effects of EBOV GP are known to be caused by a highly
glycosylated region in GP1, the mucin domain [8,12,14]. This domain encompasses
approximately 150 amino acids, contains numerous N- and O- linked glycosylation sites,
and is a unique feature of Filovirus GPs. The mucin domain is not only necessary, but
also sufficient for the observed EBOV GP-mediated effects upon surface protein
expression and cellular adhesion [8,15].
Few studies have been undertaken to investigate the mechanism by which EBOV
GP disrupts adhesion and causes surface protein down-modulation. Our recent analysis
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concluded the cellular endocytic factor dynamin does not play a role in surface protein
down-modulation, suggesting the process may not involve cycling of proteins from the
cell surface [15]. In contrast, Sullivan and colleagues have reported that this process
requires dynamin [14]. Additionally, it has been reported that the extracellular signalregulated kinases (ERK 1/2) play a role in down-modulation [16] suggesting an active
process. In the present study, we provide direct evidence that EBOV GP-mediated loss of
surface protein recognition occurs via steric shielding of surface epitopes, not by protein
removal from the cell surface. Moreover, we demonstrate that EBOV GP expression
blocks MHC1-mediated stimulation of T cells. Based upon these findings, we present a
model in which the heavily glycosylated EBOV glycoprotein acts as a “glycan shield” to
physically occlude access to host proteins, and GP itself, thereby impairing host protein
function. EBOV GP-mediated steric occlusion represents a unique viral mechanism to
interfere with the function of host proteins.
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3.3

Materials and Methods

Plasmids, cell culture and transfections
For GP studies, cDNA encoding the membrane-anchored form of Zaire EBOV
GP (Mayinga strain, accession number U23187) was used. For AU1 tagged GPs, the
amino acids, DTYRYI were added using linker insertion into GP that had been
engineered to have a unique XhoI site at position 312 encoding the amino acids LE
(NmucAU1) and a unique NotI site replacing amino acid 463 with the amino acids KRPL
(CmucAU1). EBOV GP harboring mutations in the endoproteolytic site, GP cl(-), has
been previously described [17]. All constructs were cloned into the pCAGGS expression
vector.
293T and HeLa cells were cultured in DMEM (Gibco) with 10% fetal bovine
serum (HyClone) and penicillin/streptomycin (Gibco) at 37 ºC with 5% CO2. For flow
cytometry and western blotting, 293T cells were plated in 10 cm or 6-well plates one day
prior to transfection. Cells were transiently transfected by Lipofectamine 2000 according
to manufacturer’s directions with 30 µg or 4 µg DNA per 10 cm plate or 6-well,
respectively. Immunofluorescence was performed using HeLa cells that were plated on
glass coverslips in 24-well plates and transfected with 1.5 µg DNA as above.

Antigen-presenting and primary cells
Purified CD8 T cells from normal donors were obtained from the University of
Pennsylvania Center for AIDS Research Immunology Core under a University of
Pennsylvania IRB approved protocol. The human ovarian adenocarcinoma line OV79
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has been described previously [18]. To create the OV79-SL9 antigen-presentig cells,
OV79 cells were sequentially transduced to express HLA-A*02 [19] and a construct of
GFP fused to a codon-optimized sequence of HIV-1 p17 Gag50–102. High titer lentiviral
vectors were produced as described previously [20].

Generation of SL9-specific CD8 T cells
Primary human CD8 T cells were cultured in X-Vivo 15 (Lonza) supplemented
with 5% HABS (Valley Biomedical, Winchester, VA), 2 mM GlutaMax and 25 mM
HEPES (Invitrogen). CD8 T cells were transduced to express the SL9-specific HLA-A2
restricted 869TCR as described previously [21]. Transduction efficiencies were assessed
by flow cytometric analysis of TRBV5-6 staining (anti-Vbeta5a, Thermo-Fisher) or
HLA-A*02- SL9 tetramer stain (Beckman Coulter Immunomics).

Stimulation and analysis of SL9-specific CD8 T cells
OV79-SL9 cells were plated at 16,000 cells/well on 48 well plates. After an
overnight incubation cells were transduced with adenovirus expressing GFP (Ad GFP) or
GFP and the EBOV Zaire glycoprotein (Ad GP) as described previously [12]. Briefly,
adenoviruses were diluted in media and applied to cells at an MOI of 300. Media alone
was used as a control. 48 h after transduction, target cells were analyzed for GFP and
HLA expression. Floating and adherent cells, lifted by incubation with versene, were
combined and stained for HLA-ABC or isotype control with APC-conjugated antibodies
(BD-Biosciences). Alternatively, cells were stained for different MHC1 epitopes with
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W6/32 (eBiosciences), YTH862.2 (Santa Cruz Biotechnology), BB7.2 (BD Pharmingen),
or GJ14 (Chemicon) primary antibodies, flowed by Alexa Fluor 647 (Invitrogen)
secondary antibodies. 10,000 viable (forward scatter versus side scatter) events were
collected on an LSR-II flow cytometer running BD FACSDiva-6 (BD-Biosciences), and
analyzed in FlowJo (Tree Star Inc.).
SL9-specific TCR–transduced CD8 T cells were mixed with unmodified or
adenovirally transduced OV79-SL9 target cells at a 2:1 ratio for 1 h, followed by 4 h in
the presence of brefeldin-A (Golgiplug, BD Biosciences). Stimulation with TPA (3
mg/ml, Sigma-Aldrich) and ionomycin (1 mg/ml; Calbiochem) with brefeldin-A was
used as positive control. Cells were washed in PBS and surface-stained using CD8
conjugated to APC-H7, and then fixed and permeabilized with the Caltag Fix & Perm kit
(Invitrogen) and stained using anti-TRBV5-6 FITC and macrophage inflammatory
protein-1b (MIP-1b, CCL4)-PE. Sequential gates of 10,000 viable (forward scatter versus
side scatter), CD8 positive events were acquired for all conditions on an LSR-II flow
cytometer running BD FACSDiva-6 (BD-Biosciences). Data were analyzed for cytokine
production in FlowJo (Tree Star Inc.).

Cell lysates and western blotting
Transfected cells were removed by resuspension in the culturing media. Cells
were pelleted at 4 ºC for 3 min at 1300 x g. Pellets were resuspended in 1% Triton X-100
or RIPA buffer with complete protease inhibitor cocktail (Roche) for 5 minutes. Lysates
were cleared by centrifugation at 4 ºC at 20,800 x g. 30 µl samples were mixed with
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reducing SDS buffer, boiled for 5 minutes, and separated on a 4-15% Criterion PAGE gel
(Bio-Rad). Proteins were transferred to PVDF (Millipore) at a 400 mA constant current.
Membranes were blocked in 5% milk in TBS. Membranes were probed with rabbit
polyclonal anti-GP sera which recognizes the GP1 subunit [22], rabbit anti-AU1
antibodies (Bethyl labs), or anti-GAPDH monoclonal antibodies (Calbiochem) in
blocking buffer. Protein was detected with stabilized goat anti- rabbit or mouse HRP
conjugated antibodies (Pierce) in blocking buffer. Membranes were visualized with
SuperSignal Femto substrate (Pierce).

Flow cytometry
293T cells were detached from the plate 24 hours post transfection with PBS -/-,
0.5 mM EDTA and combined with floating cells in culture media. Alternatively, floating
cells in cluture media were removed and used exclusively (where indicated). Cells were
pelleted at 4 ºC at 250 x g, then resuspended in flow wash buffer (PBS -/- with 1% bovine
calf serum and 0.05% NaAzide) and aliquoted for staining. For detection of EBOV GP,
cells were stained with the human MAb, KZ52 [23] and detected with FITC anti-human
IgG (PharMingen). For detection of AU1 epitopes, cells were stained with rabbit
polyclonal anti-AU1 antibodies (Bethyl labs) and detected with FITC goat anti-rabbit IgG
(Rockland). For detection of β1 integrin, cells were stained with anti-human CD29 PECy5 conjugate (eBioscience); for detection of MHC1, cells were stained with anti- HLAABC PE-Cy5 conjugate (eBioscience). For intracellular staining, cells were
permeabilized using Cytofix/Cytoperm (BD Biosciences) for 20 min on ice, followed by
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washing with Permwash (BD Biosciences). Antibodies where then diluted in Permwash
buffer. For detection of GM130 and calnexin, mouse monoclonal FITC-conjugated
antibodies were used (BD Transduction Labs). All staining was performed on ice,
followed by washing. Live cell gates were drawn based on forward and side scatter. For
each sample, 10,000 or 20,000 events in the live cell gate were collected and analyzed.
Data were collected on a Becton Dickinson FACSCalibur and analyzed using FlowJo
software (Tree Star, Inc.).

Immunofluorescence microscopy
For HeLa cells, media was removed at 24 hours post-transfection, cells were
washed with PBS and fixed with 3% PFA in PBS for 20 minutes. For non-adherent 293T
cells, media containing floating cells was removed from plate, then centrifuged onto
poly-D-lysine coated coverslips (BD Biosciences), then fixed. All samples were then
washed with PBS, then permeabilized with 0.2% saponin, 1% goat serum in PBS for 5
minutes, then washed with PBS. Cells were blocked with 10% goat serum, 0.1% Tween20 in PBS for 2 hours. For GP staining, coverslips were incubated with mouse antiEBOV GP MAb 42/3.7 (gift from Yoshihiro Kawaoka) and detected with goat anti-rabbit
Alexa Fluor 594 antibodies (Invitrogen). For AU1 staining, coverslips were incubated
with rabbit anti-AU1 antibodies (Bethyl labs) and detected with anti-rabbit Alexa Fluor
488 antibodies (Invitrogen). Cells were washed with PBS after each staining step.
Coverslips were mounted on glass slides with mounting medium containing DAPI
(Vectasheild). Z-section images were collected on a Leica DMRE fluorescence
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microscope using Open Lab software (Improvision). Thirty z-sections per image were
collected at 0.2 µm intervals. Z-section data were deconvoluted using Velocity software
(Improvision) to a 98% confidence level or 15 iterations. Images shown are single,
deconvoluted, z-sections.

DTT treatment
At 24 hours post-transfection, sodium azide was added to 0.1% and 2-deoxy
glucose was added to 10 mM. Cells were incubated an additional 30 min. Cells were then
harvested and resuspended in flow wash buffer supplemented with 0.1% azide and 10
mM 2-deoxy glucose. DTT was then added to 150 mM and cells were incubated at 37 ºC
for 20 minutes. Cells were then pelleted at room temperature and the supernatant was
removed and blotted for GP as described above. Cells were then washed twice in flow
wash and stained for flow cytometry as described above.

Glycosidase treatment
At 24 hours post-transfection, floating cells were harvested and resuspended in
100 µl flow wash buffer. 100 U of neuraminidase (NEB) and/or 1000 U of PNGaseF
(NEB) was then added. Cells were then incubated at 37 ºC for 20 minutes. Cells were
then washed twice and aliquoted for flow cytometry or western blotting as described
above. Alternatively, cells were incubated with 2 mM benzyl-α-GalNAc (Sigma) or
DMSO at 31 ºC for 48 hours. Cells were then given fresh media with 2 mM benzyl-αGalNAc or DMSO and cultured at 37 ºC for 1 hour. Cells were then transfected as
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described above. At 24 hours post-transfection, floating and adherent cells were
harvested and resuspended in 100 µl flow wash buffer. 1000 U of PNGaseF (NEB) or 2.5
mU of O-glycosidase (Sigma) was then added. Cells were then incubated and analyzed as
above. For PNGaseF treatment of cell lysates, 30 µl of lysate was incubated with
glycoprotein denaturing buffer (NEB) for 10 minutes at 60 ºC. Samples were then
incubated with G7 buffer, NP40, and 500 U PNGase F (NEB) for 2 hours at 37 ºC, then
blotted for GP as described above.
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3.4

Results

EBOV GP expression blocks surface protein staining
EBOV GP expression can dramatically reduce the levels of numerous host cell
surface proteins including factors involved in immune recognition and cellular adhesion
[10,12,14]. This effect can be seen by analysis of MHC1 or β1 integrin by flow
cytometry in HEK293T cells transiently expressing Zaire EBOV GP (Figure 3-1 A).
Overall, a 10- to 50-fold reduction in surface levels of these host markers is observed in
cells transfected with an EBOV GP cDNA. Additionally, there appears to be a critical
threshold of EBOV GP expression required to induce surface protein down-modulation
[15]. In parallel with the decrease in staining for host proteins, EBOV GP expression
also appears to be reduced, resulting in a distinctive comma-shaped FACS profile (Figure
3-1 A and [14,15,16]). Despite this apparent decrease in surface protein levels observed
by flow cytometry, there were no consistent, significant changes in total protein levels for
the EBOV glycoprotein upon analysis by western blot in either adherent or non-adherent
EBOV GP transfected cells (data not shown). To look directly at host protein expression
in cells expressing GP, nonadherent, GP-transfected 293T cells were collected and
analyzed by flow cytometry for expression of β1 integrin ([15] and Figure 3-1 B, left
panel). As previously described [15], these nonadherent cells represent the lower two
quadrants of the “comma” and appear to have reduced levels of both β1 integrin and
EBOV GP. In contrast to the FACS results, analysis of EBOV GP in these cells by
immunofluorescence microscopy after fixation and permeabilization reveals extensive
staining at the plasma membrane (Figure 3-1 B, right panel).
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Figure 3-1
Transient expression of the EBOV glycoprotein results in loss of
surface staining of β1 integrin and MHC1. (A) 293T cells were transfected with empty
pCAGGS (vector) or vector encoding GP. Floating and adherent cells were harvested 24
h after transfection, pooled, and stained for GP using the KZ52 antibody, followed by
FITC-labeled secondary antibodies, and co-stained for β1 integrin or MHC1 with PE-Cy5
conjugated monoclonal antibodies and assayed by flow cytometry. (B) Following
transfection with vector encoding GP, floating 293T cells were removed from adherent
cells, stained for β1 integrin and assayed by flow cytometry (left panel). Similarly treated
cells were mounted on coverslips, fixed, permeabilized and stained for GP with mouse
monoclonal antibodies, followed by Alexa 594 conjugated antibodies and assayed by
immunofluorescence microscopy. A representative cell is shown (right panel).
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Similar to these results, previously published microscopic analysis of cells expressing
EBOV GP also shows extensive plasma membrane staining with little evidence of
significant accumulation of GP in internal vesicles [15,24].
To evaluate steady state levels of host proteins and EBOV GP in cells transiently
expressing the EBOV glycoprotein, the transfected cells were fixed, permeabilized and
analyzed by flow cytometry. In vector-transfected cells, the permeabilization treatment
had little effect upon staining for β1 integrin or MHC1 (Figure 3-2 A). However, in cells
transiently expressing EBOV GP, which displayed dramatically reduced levels of β1
integrin and MHC1 by surface staining (Figure 3-2 B, left column), fixation and
permeabilization reveals no decrease in either of these host proteins (Figure 3-2 B, right
column). Similarly, the apparent loss of EBOV GP staining is reversed by this treatment.
These effects are best illustrated by comparison of the lower two panels in Figure 3-2 B
where without treatment, 9.3% of the cells displayed low MHC1 and EBOV GP levels,
however after fixation and permeabilization the number of double negative cells was
reduced to background levels and these now appear as MHC+, GP+ cells in the upper
right quadrant. As expected, the untransfected cell population of 32-34% remains
unaltered by this treatment (Figure 3-2 B, upper left quadrants). Overall, this analysis
suggests that the apparent down-modulation observed is not due to reduced steady-state
levels of protein. Rather these transfected cells express unaltered levels of EBOV GP and
MHC1, however these proteins are inaccessible for surface staining.
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Figure 3-2
Steady-state levels of β1 integrin and MHC1 are unchanged in GPexpressing cells. 293T cells were transfected with empty vector (A) or vector encoding
wt GP (B). Floating and adherent cells were harvested 24 h after transfection, pooled, and
stained for GP, β1 integrin, and MHC1 as described earlier and assayed by flow
cytometry. Prior to staining, a portion of cells were fixed and permeabilized to expose
occluded surface and internal epitopes.
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EBOV GP shields its own epitopes at the cell surface
Recent structural analysis of EBOV GP suggests that the recognition site for the
monoclonal antibody, KZ52, employed in the FACS analysis resides near the base of the
protein [25] below the globular GP1 and heavily glycosylated mucin domains in GP.
This finding, coupled with our results suggesting that down-modulation in these cells was
not accompanied by a reduction in steady-state levels of β1 integrin or MHC1, or a
significant re-localization of EBOV GP, prompted us to consider the hypothesis that
EBOV GP mediates its effects by blocking access to surface epitopes. Additionally, this
hypothesis is consistent with the apparent threshold of GP expression required for downmodulation as well as the lack of a dynamin requirement [15].
To test this hypothesis, we engineered epitopes within EBOV GP at locations
which, based on their position relative to the mucin domain and the globular region of
GP, are predicted to be more accessible than the KZ52 epitope. Two constructs were
created with an AU1 antibody epitope tag at the N or C terminus of the mucin domain,
termed NmucAU1 GP and CmucAU1 GP, respectively. Cartoon depictions of each
construct are shown in Figure 3-3 C and D. These constructs were well expressed, as
judged by western blot analysis for EBOV GP and the AU1 tag (Figure 3-3 A). The subcellular localization of these constructs was also evaluated in HeLa cells by
immunofluorescence microscopy and was found to be indistinguishable from wt GP
(Figure 3-3 B).
Although the structure of the mucin domain is unknown, its mucin-like O
glycosylation may force the domain into an extended conformation as has been
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Figure 3-3
The mucin and globular domains of the EBOV glycoprotein mask the
KZ52 epitope on the cell surface. (A) 293T cells were transfected with empty vector or
vector encoding wt GP, CmucAU1 GP, or NmucAU1 GP. Lysates were harvested in
RIPA buffer after 24 h and subjected to SDS-4 to 15% PAGE, transferred to PVDF, and
immunoblotted with anti-GP polyclonal rabbit antibodies (top blot) or anti-AU1
antibodies (bottom blot) and anti-GAPDH antibodies. (B) HeLa cells were transfected
with vector encoding wt GP, CmucAU1 GP, or NmucAU1 GP. 24 h after transfection,
cells were fixed, permeabilized, and stained for GP with mouse monoclonal antibodies,
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and the AU1 epitope with anti-AU1 antibodies, followed by Alexa 594 and Alexa 488
conjugated antibodies, respectively and assayed by immunofluorescence microscopy.
Scale bars are 10.6 µm. (C, D) 293T cells were transfected with vector encoding wt GP,
CmucAU1 GP, or NmucAU1 GP. Floating and adherent cells were harvested 24 h after
transfection, pooled, and stained for GP using the KZ52 antibody or the AU1 tag, β1
integrin, and MHC1, as described earlier and assayed by flow cytometry. (C) β1 integrin
vs. GP or AU1 surface staining. (D) MHC1 vs. GP or AU1 surface staining. Cartoon
depictions of the KZ52 epitope (red star), CmucAU1 epitope (green star) or NmucAU1
epitope (yellow star) are shown below their respective flow cytometry plots. The globular
region of GP is shown shaded blue; the mucin domain is shown shaded green.
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suggested for cellular mucin proteins [26]. This would place C terminus of the mucin
domain distal from the rest of the domain and the other globular GP domains (Figure 3-3
C and D). Based upon the proposed steric occlusion model, we hypothesized that the
AU1 epitope of CmucAU1 would be most accessible to antibody staining. In contrast,
the AU1 epitope in NmucAU1 might be less accessible than the epitope in CmucAU1
because of its location at the base of the mucin domain. Cells expressing wt GP,
CmucAU1 GP, and NmucAU1 GP were analyzed by flow cytometry. When stained with
the GP-specific KZ52 antibody, the epitope-tagged mutants displayed the characteristic
comma-shaped FACS plot seen with wt GP (Figure 3-3 C and D; top rows). In contrast to
the reduced KZ52 staining observed, the AU1 epitope in CmucAU1 was highly visible by
flow cytometry (Figure 3-3 C and D; bottom middle panels). Staining of the AU1 epitope
on NmucAU1 GP was intermediate relative to CmucAU1 GP and wt GP KZ52 staining
(Figure 3-3 C and D; bottom right panels). In support of the shielding model, these data
demonstrate that cells exhibiting reduced levels of β1 integrin and MHC1 have high
surface levels of GP as indicated by AU1 staining, not reduced levels as indicated by
KZ52 staining. Furthermore, these data suggest that antibody accessibility to epitopes in
GP differs based on the epitope position relative to the mucin domain and the globular
regions of GP1.

Removal of the EBOV GP1 subunit reveals shielded host surface proteins
The data presented above are consistent with EBOV GP affecting recognition of
epitopes within GP by shielding, however we wished to address if a similar mechanism
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was responsible for the apparent down-modulation of host surface proteins. To directly
address whether EBOV GP sterically occludes host surface protein epitopes, we sought to
unmask MHC1 and β1 integrin staining. We hypothesized that dissociation of the GP1
subunit, which includes the mucin domain and globular “head” region of EBOV GP,
from GP2 at the cell surface should relieve the shielding of previously occluded epitopes.
The GP1 subunit is covalently linked to GP2 via a single sulfahydryl bridge between
residues C53 and C609 [7]. We have previously demonstrated that this bond can be
reduced by incubation with DTT, allowing for dissociation of the EBOV GP1 subunit
from the surface of virions [17]. To confirm that DTT is able to effectively remove GP1
from the cell surface, cells expressing GP were incubated with DTT then the supernatant
was analyzed for GP by western blot. Figure 3-4 A reveals that GP1 was readily detected
in the supernatant of cells incubated with DTT compared to mock treated cells. Control
experiments also demonstrated that the DTT treatment did not significantly alter surface
expression of β1 integrin or MHC1 in mock-transfected cells (Figure 3-4 B).
Additionally, this treatment did not result in permeabilization of the cells (Figure 3-4 C)
which, as shown above (Figure 3-2), could also rescue β1 integrin and MHC1 staining. In
addition, these and the following experiments were carried out in the presence of azide
and 2-deoxy glucose to ensure that the trafficking of nascent or recycled protein did not
complicate the interpretation of this assay.
We next examined the effect of DTT treatment on surface staining of β1 integrin
and MHC1 in cells expressing EBOV GP. FACS analysis of the DTT-treated, GP-
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Figure 3-4
Removal of the GP1 subunit from the cell surface results in exposure
of previously occluded surface epitopes. (A-C) 293T cells were transfected with empty
vector or vector encoding wt GP. Floating and adherent cells were harvested 24 h after
transfection, pooled, and either left untreated, or incubated at 37 ºC for 20 minutes in 150
mM DTT. (A) Western blot analysis of the GP1 subunit shed into the supernatant of
untreated or DTT-treated cells. (B) Cells were transfected with empty vector and assayed
by flow cytometry to show baseline differences in surface staining for β1 integrin and
MHC1 between untreated cells (grey shading) and DTT-treated cells (black trace). (C)
Cells were transfected with vector encoding wt GP and assayed by flow cytometry for the
internal proteins GM130 and calnexin to show the effect of DTT on cell
permeabilization. Untreated cells are shown in the grey shading; DTT-treated cells are
shown in the black trace, and, as a positive control, fixed/permeabilized cells are shown
in the dashed trace. (D) Cells were transfected with vector encoding wt GP, were mockor DTT-treated, stained for GP and β1 integrin or MHC1 as described above, and assayed
by flow cytometry. (E, F) 293T cells were transfected with empty vector or vector
encoding wt GP or GP cl(-). Cells were harvested and treated as above. (E) Western blot
analysis using rabbit polyclonal antibodies of GP1 or GP0 shed into the supernatant of
untreated or DTT-treated cells. (F) Transfected and treated cells were surface stained for
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MHC1 and assayed by flow cytometry. Empty vector-transfected, untreated cells are
shown in the grey shading; GP-expressing cells are shown after mock treatment (black
trace) or DTT treatment (dashed trace).
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expressing cells indicates that GP-induced loss of staining of β1 integrin and MHC1 is
reversed by DTT treatment and subsequent dissociation of GP1 from the cells: upon DTT
treatment, staining of β1 integrin and MHC1 is restored to nearly control levels (Figure
3-4 D). Interestingly, staining for GP was also rescued, resulting in cells that stained
positively for both GP and β1 integrin or MHC1. This is somewhat counter-intuitive, as
KZ52 makes critical contacts with residues on GP1 [25], which is removed from the cell
surface by DTT. These data suggest that DTT treatment removes a significant amount of
GP1 from the cell surface – enough to reverse the steric occlusion of β1 integrin and
MHC1 epitopes, as well as the KZ52 epitope. However, sufficient GP1 remains on the
cell surface to allow for staining of GP by flow cytometry. This finding agrees with our
previously published study that suggests a threshold level of EBOV GP is needed to
downmodulate β1 integrin, MHC1 or GP [15].
Removal of surface GP1 by DTT reverses the apparent down-modulation of
surface proteins induced by EBOV GP. To ensure this effect could be directly attributed
to the EBOV glycoprotein we tested the effect of DTT on cells expressing a mutant form
of GP lacking the endoproteolytic site required for processing GP0 into GP1 and GP2
subunits. Previous analysis demonstrated that this mutant EBOV glycoprotein, GP cl(-),
retains normal viral entry function [17,27] and is therefore likely folded similarly to wt
EBOV GP. As shown in Figure 3-4 F, GP cl(-) also downmodulates MHC1 similarly to
wt EBOV GP. However in contrast to wt GP, DTT treatment of cells expressing this
uncleaved form of GP does not relieve the observed down-modulation of MHC1 (Figure
3-4 F). As anticipated, DTT treatment of cells expressing GP cl(-) produced no increase
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in GP release compared to untreated cells (Figure 3-4 E). The EBOV glycoprotein found
in the supernatant from the GP cl(-) expressing cells likely represents trimeric GP
released by the cellular enzyme TACE [28]. Overall, these data strongly support the
model proposed for EBOV GP mediated occlusion of host surface proteins.

Carbohydrate modification of GP is important for steric shielding
GP is a heavily glycosylated protein, and we have previously shown the mucin
domain to be sufficient to induce loss of staining of host surface proteins by flow
cytometry [15]. Therefore, we directly addressed whether GP glycosylation plays a role
in the shielding of surface epitopes. GP-expressing cells were treated with several
glycosidases or pre-treated with a small molecule inhibitor of mucin synthesis, benzyl-αGalNAc, then assayed for β1 integrin staining by flow cytometry. Importantly, none of
the glycan-interfering treatments used here increased the staining for β1 integrin in cells
transfected with empty vector (Figure 3-5 A). Also, these treatments did not cause the
permeabilization of cells, allowing us to attribute changes in staining to alterations at the
cell surface (Figure 3-5 B). Staining for β1 integrin on GP-expressing cells was
increased by incubation with PNGaseF, an endoglycosidase that cleaves all N-linked
sugar moieties (Figure 3-5 D left). Similarly, staining for β1 integrin was increased by
incubation with neuraminidase, an exoglycosidase that cleaves sialic acid, which is a
common component of mucin sugars. (Figure 3-5 D, middle). When GP-expressing cells
were incubated with both PNGaseF and neuraminidase, an additive effect was seen and
β1 integrin staining was further increased (Figure 3-5 D, right). The effect of glycosidase
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Figure 3-5
Surface N- and O- linked glycans contribute to GP-mediated
shielding. (A, left plot) Cells transfected with empty vector were mock incubated (grey
shading) or incubated with neuraminidase and PNGaseF (black trace), stained for β1
integrin and assayed by flow cytometry. (A, right plot) Cells were treated with DMSO,
transfected with empty vector, and mock incubated (grey shading) or treated with benzyl101

Chapter 3
α-GalNAc (bz-GalNAc), transfected with empty vector, and incubated with PNGaseF
(black trace), then stained for β1 integrin and assayed by flow cytometry. (B) Cells were
left untreated and untransfected (grey shading), or treated with benzyl-α-GalNAc,
transfected with vector encoding GP, and incubated with PNGaseF (black trace), then
assayed by flow cytometry for the internal proteins GM130 and calnexin to show the
effect of these treatments on cell permeabilization. As a positive control, benzyl-αGalNAc-treated, fixed/permeabilized cells are shown (dashed trace). (C, D) Floating cells
in cultures transfected with vector encoding GP were mock incubated or incubated with
neuraminidase and/or PNGaseF, then analyzed by western blot with rabbit polyclonal
antibodies to GP (C, left blot) or stained for β1 integrin and assayed by flow cytometry
(D). (C, E) Cells were treated with DMSO or bz-GalNAc, then transfected with empty
vector, or vector encoding GP. Cells were then mock-incubated, or incubated with
PNGaseF, then analyzed by western blot (C, right blot) or stained for β1 integrin and
assayed by flow cytometry (E). For D and E, mock-incubated cells or DMSO-treated
cells transfected with empty vector= grey shading; GP-transfected and DMSO-treated or
mock-incubated cells= black traces; GP-transfected and bz-GalNAc- and glycosidasetreated cells= dashed traces. In western blot panels (C), selected samples were lysed and
denatured before incubation with PNGaseF for comparison, as indicated.
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treatment on cellular GP was also analyzed by western blot (Figure 3-5 C, left). PNGaseF
treatment results in loss of the top band of GP1, which is the maturely- glycosylated form
and the appearance of bands which co-migrate with GP1 that has been PNGaseF treated
under denaturing conditions, but which still contains O glycosylation. Treatment with
neuraminidase did not result in a perceivable shift in migration of GP1; this is likely due
to the small mass of these glycans and the resolution of the gel. These data indicate a
direct role for N-linked glycans in GP-mediated loss of β1 integrin staining.
To directly address the role of O glycosylation in host protein down-modulation
by EBOV GP, O glycosylation was perturbed by pre-incubating cells with benzyl-αGalNAc or the control vehicle DMSO. This compound is a competitive inhibitor of β1,3galactosyltransferase, which prevents the modification of core O glycan structures,
resulting in shorter O-linked glycans and reduced sialyation [29,30,31]. Cells pre-treated
with benzyl-α-GalNAc, then transfected with vector encoding GP showed increased
staining for β1 integrin compared to DMSO treated cells, consistent with a role for O
glycoslyation in the shielding of epitopes by the GP mucin domain (Figure 3-5 E, left
plot). In cells pre-treated with benzyl-α-GalNAc and expressing GP, incubation with
PNGaseF further increased staining for β1 integrin (Figure 3-5 E, right plot). Cells pretreated with benzyl-α-GalNAc were also incubated with O-glycosidase, which can cleave
unmodified core GalNAc structures; however, no further increase in β1 integrin was
observed (data not shown). This is perhaps due to remaining modification of the core O
glycans. The effect of these treatments on GP glycosylation was analyzed by western blot
(Figure 3-5 C, right blot). Treatment with benzyl-α-GalNAc results in a modest increase
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in mobility for bands corresponding to GP containing O glycosylation, which are most
easily seen in samples that have been PNGase-treated after cell lysis. Our data here
suggest that the mass of O glycosylation is reduced, but not fully eliminated. This is
expected, as benzyl-α-GalNAc only reduces mucin modification, but does not prevent the
synthesis of initial core glycans. Taken together, these data demonstrate that surface Nand O- linked glycans, presumably on EBOV GP, contribute to the ability of GP to mask
surface β1 integrin epitopes.

EBOV GP expression blocks MHC1 mediated T cell activation
In cells expressing GP, we observed that staining for MHC1 is blocked regardless
of the epitope examined (Figure 3-6). Given the ability of EBOV GP to mask spatially
separate epitopes on MHC1, we wanted to address whether this had functional
consequences for MHC1. Human OV79 cells expressing the HIV Gag-derived peptide
SLYNTVATL (SL9) were used to test the effect of EBOV GP on MHC1 antigen
presentation. These cells present the SL9 antigen using a stably expressed MHC1, HLAA2. The OV79- SL9 cells were mock transduced or transduced with adenoviral vectors
encoding GFP (AdGFP) or GFP and EBOV GP (AdGP), which resulted in nearly 100%
of cells expressing GFP (Figure 3-7 A). Expression of EBOV GP dramatically reduced
MHC1 levels in these cells whereas the control GFP vector had no effect on MHC1
expression (Figure 3-7 B). Primary human CD8 T cells transduced with a lentiviral vector
expressing a T cell receptor (868TCRwt) specific for SL9 were used to assess antigen
presentation by GP-expressing OV79 cells. T cell activation was measured by
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Figure 3-6
EBOV GP masks multiple
epitopes on MHC1. OV79 SL9 target cells
were mock transduced or transduced with
Adenoviral vectors expressing GFP (Ad GFP)
or GFP and EBOV GP (Ad GP) at an MOI of
300. 48 h after transduction, cells were
indirectly stained for different epitopes on
MHC1 with primary antibody clones W6/32,
YTH862.2, BB7.2 and GJ14 and detected
with Alexa Fluor 647-conjugated secondary
antibodies; isotype antibody= grey peak;
mock transduction= blue trace; Ad GFP=
green trace; Ad GP= orange trace. The
approximate location of each epitope is
marked by the yellow star in a cartoon
depiction of MHC1 to the right of each graph.
The W6/32 clone recognizes the MHC1
heavy chain and the β2 microglobulin. The
YTH862.2 clone recognizes the α1 domain of
the MHC1 heavy chain. The BB7.2 clone is
specific for HLA-A2 and recognizes the α2
domain of the heavy chain. The GJ14 clone
recognizes the β2 microglobulin.
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intracellular staining for production of the cytokine MIP-1β in CD8+ 868TCRwt+
expressing cells (Figure 3-7 C). Production of MIP-1β has been shown to be the most
sensitive indicator of HIV-specific CD8 T cell activation [32]. Quantification of the CD8
activation results demonstrates that expression of EBOV GP had a profound effect on
antigen presentation by the target cells, reducing T cell responses to nearly background
levels (Figure 3-7 D). In contrast, the AdGFP control cells only modestly reduced the
number of responding T cells. Similar results were obtained using 293T target cells (data
not shown). Thus EBOV GP expression not only masks epitopes on MHC and other
surface proteins, it also functionally inactivates them.
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Figure 3-7
EBOV GP-induced disruption of MHC1 prevents the activation of
+
CD8 T cells. OV79 SL9 target cells were mock transduced (no Ad) or transduced with
Adenoviral vectors expressing GFP (Ad GFP) or GFP and EBOV GP (Ad GP) at an MOI
of 300. 48 h after transduction, cells were assayed for GFP expression (A); No Ad= blue
trace; Ad GFP= green trace; Ad GP= orange trace. Cells were also stained for MHC1
(B); isotype antibody= shaded peak; No Ad= blue trace; Ad GFP= green trace; Ad GP=
orange trace. In parallel, CD8 T cells expressing a transgenic TCR (868TCRwt) that
recognizes the SL9 HLA-A2 complex were incubated alone or with mock- (no Ad) or
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Ad- transduced target cells in a 2:1 ratio. After co-culture, T cells were surface stained
for CD8, then fixed and permeabilized, and stained for 868TCRwt and MIP-1β with
APC-H7, FITC, and PE- conjugated antibodies, respectively, and assayed by flow
cytometry. (C) CD8+ and 868TCRwt+ events were analyzed for MIP-1β staining. (D) Bar
graph depicts percent cells positive for MIP-1β, normalized to the No Ad target cell
sample.
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3.5

Discussion
An important component of the virus host interaction is viral modulation of host

functions. Many viruses alter expression and/or function of host surface proteins to affect
signaling, immune surveillance, or viral superinfection. EBOV GP expression in cell
culture has been observed by several groups to cause dramatic changes in cell adhesion
and reduction in surface protein staining by flow cytometry [10,12,14,16]. EBOV
infection causes a similar reduction of β1 integrin and MHC1 staining by flow cytometry,
suggesting that observations from transient GP expression are not simply artifacts of
overexpression [3]. EBOV GP-induced effects have previously been assumed to result
from removal of surface proteins from the plasma membrane. In this study we analyzed
the mechanism of down-modulation of host surface proteins by the EBOV viral
glycoprotein, GP. We show that reduction in surface staining for the host proteins MHC1
and β1 integrin is not accompanied by decreases in the total cellular levels of these
proteins. Moreover, the observed self down-modulation of EBOV GP does not result in
relocalization of GP away from the plasma membrane. Using epitopes placed at various
locations in EBOV GP we find that the observed GP surface levels appear to differ based
on epitope position relative to the mucin domain and the globular regions of the EBOV
GP. A similar observation has been made using a series of monoclonal antibodies to
EBOV GP [33]. Additionally, the apparent down-modulation of surface proteins is
reversed by removal of the EBOV GP1 subunit by reduction or by enzymatic digestion of
the carbohydrate modification on EBOV GP. Finally, our data demonstrate that EBOV
GP expression dramatically impairs antigen presentation by host cells. Taken together
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these data support a model in which EBOV GP utilizes a steric occlusion mechanism to
downmodulate accessibility and function of host surface proteins.
The ability of viruses to affect host surface proteins has been well documented.
For example, viruses may down-regulate their cellular receptor, as in the case of HIV
down-regulation of CD4 and measles virus down-regulation of the complement
regulatory protein [34,35]. Other common targets for virus mediated down-modulation
are surface proteins related to immune surveillance. MHC1 is known to be downregulated from the cell surface by many viral proteins: HIV nef, Adenovirus E19, and
KSHV K3 and K5, to name a few [36,37,38]. Activating ligands for natural killer (NK)
cells have also been shown to be actively down-regulated by KSHV and Hepatitis C virus
[39,40]. Multiple mechanisms and cellular pathways have been implicated in viral
dysregulation of the various host surface molecules (reviewed for MHC1 in [41]). The
model demonstrated here of glycan mediated steric occlusion by EBOV GP represents, to
our knowledge, a unique mechanism for viral regulation of host surface proteins. Indeed,
a similar steric masking model has recently been proposed for EBOV GP [33]. The
polydnavirus, Microplitis demolitor bracovirus expresses a mucin domain-containing
glycoprotein which can abrogate cell adhesion and thus may utilize a mechanism similar
to that proposed here for EBOV [42].
Our observation that enzymatic removal of carbohydrate modification can relieve
down-modulation, coupled with prior observations that the mucin domain of EBOV GP
is sufficient for down-regulation [8,15], suggests that the steric occlusion observed is
mediated, at least in part, by N- and O-linked modification of EBOV GP. A similar
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glycan mediated steric hindrance model has been proposed for cellular mucin proteins,
which can disrupt a variety of cell-cell interactions at the plasma membrane
[43,44,45,46,47]. For the cellular mucin proteins, densely-arrayed O-linked glycans are
critical for disruption of cell adhesion, with different core glycan structure and
subsequent modifications influencing the function and anti-adhesive properties of the
protein [48]. Additionally, the number of mucin tandem repeats positively correlates
with the anti-adhesive properties of Muc1 [47]. Similarly, we have shown that sequential
removal of glycosylation sites in the mucin domain of EBOV GP led to a step-wise
reduction in cell detachment suggesting that such modifications within GP are involved
in down-modulation [12]. The O-linked glycosylation found on the EBOV GP mucin
domain may promote an extended conformation as is seen for cellular mucin proteins
[26] allowing this domain in GP to act as an approximately 150 residue long flexible rod
that can protrude and mask epitopes in the immediate vicinity.
The ability of carbohydrate modification to protect epitopes on the surface of a
viral glycoprotein is well established. Indeed, a glycan shield model has been proposed
for other viral glycoproteins, most notably HIV, as a mechanism to avoid host immune
recognition [49]. An extended glycosylated protrusion provided by the mucin domain
may be a characteristic feature that distinguishes EBOV GP from other viral
glycoproteins where the glycan shield does not cause steric occlusion of host factors.
Another feature of the proposed model is that EBOV GP must localize in close proximity
to the affected proteins; perhaps within plasma membrane microdomains inhabited by the
host proteins. This requirement may explain the critical threshold for the observed GP
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effects as well as the variety of proteins regulated by EBOV GP. It may be that the
ability to occupy these microdomains is, in addition to the extensive carbohydrate
modification, a characteristic feature of EBOV GP. Based upon our results it appears
likely, therefore, that the heavily glycosylated EBOV GP acts as a glycan shield to
physically occlude access to nearby host proteins, and GP itself, thereby impairing host
protein function.
It is intriguing to consider the role in EBOV replication or pathogenesis of GPinduced steric occlusion of surface proteins. Based upon our observations of proteins at
the plasma membrane it is plausible that EBOV GP functions to shield epitopes on the
surface of virions thereby contributing to infection and/or persistence in the natural
reservoir. Notably the KZ52 monoclonal antibody employed in these studies is
neutralizing but fails to protect nonhuman primates from EBOV infection [23,50].
Perhaps variation in GP density on virions produced in vivo differentially affects the
neutralization sensitivity of viruses in nonhuman primates. Additionally, the ability of GP
to mask MHC1 and inhibit cell-cell adhesion may be a strategy for avoiding CD8 T cellmediated killing of infected cells. Our data demonstrating that GP-expressing cells do
not effectively activate CD8 T cells supports this hypothesis. Interestingly, this
mechanism is proposed for adenocarcinomas, in which cellular mucin protein
overexpression can result in metastasis due to loss of adhesion, and has been shown to
prevent recognition and killing by NK and cytotoxic T cells [44,51,52]. However, the
rapid time course of EBOV infection and its impairment of adaptive responses may
render escape from CD8 cells unnecessary in humans. Instead, protection from NK cells
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may be more important and the ability of EBOV GP to affect NK cell recognition should
be explored. Alternatively, the ability to mask MHC1 may be more critical for viral
infection or persistence in the natural reservoir for EBOV. Finally, it is known that the
interface between the innate and adaptive immune response is affected during EBOV
infection (reviewed in [2]). We have previously shown that EBOV GP causes rounding in
macrophages [12]. It is possible that EBOV GP shielding and inhibition of adhesion
molecules or other immune regulatory proteins on professional antigen presenting cells
such as macrophage or dendritic cells plays a role in the immune dysfunction
characteristic of EBOV infection.
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Abstract
The Ebola virus (EBOV) is highly pathogenic in humans and non-human primates

with mortality rates reaching 90%. Our understanding of EBOV pathogenesis is limited,
though it is generally understood that the immune response is severely disrupted during
infection. Terminally-infected patients are unable to mount a significant adaptive immune
response and show low or no significant EBOV specific antibody production. The
underlying mechanisms for this immune dysfunction are not completely understood but
are likely complex. In previous reports we have demonstrated that a neutralizing
antibody, KZ52, which is directed against the EBOV glycoprotein (GP), is sterically
blocked from binding to GP at the cell surface by heavily-glycosylated domains within
GP, itself. In the current study, we address the possibility that steric occlusion of the
KZ52 antibody may also occur on the surface of viral particles. First, we characterize a
construct of GP that undergoes processing in the secretory system to remove the mucin
and glycan cap domains of GP. This “primed GP” allowed us to identify the glycan cap
as responsible for the shielding of the KZ52 epitope at the cell surface. We then
demonstrate that full-length GP interferes with the amount of antibody that can bind on
retroviral particles, indicating that steric occlusion occurs on the virion surface.
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Interestingly, despite differences in antibody access, neutralization of retroviral particles
bearing occluding or non-occluding forms of GP seems unaffected. These data suggest a
novel role for the glycosylated domains of GP in blocking antibody access to viral
particles and warrant further studies into this mechanism to expand our understanding of
the interplay between GP and the immune response to EBOV.
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4.2

Introduction
The Ebola virus (EBOV) is a member of the family, Filoviridae, and is the

etiological agent of Ebola hemorrhagic fever (EHF). Generally, EHF is associated with
extremely high levels of morbidity and mortality in humans and nonhuman primates,
although different subtypes of EBOV are differently pathogenic in humans. The five
subtypes of EBOV- from most to least pathogenic- are Zaire, Sudan, Bundibugyo, Côte
d'Ivoire, and Reston [1,2]. The basis for the high pathogenicity of certain subtypes of
EBOV is unclear, however immune dysregulation likely plays a role [3]. It has been
noted during outbreaks of EHF, that infected patients who succumb to EBOV show little
or no signs of adaptive immunity. These patients do not make EBOV- specific antibodies
and do not undergo class switching from IgM to IgG, an indicator of a productive B cell
response [4,5,6]. In contrast, patients who survived EHF were able to make IgG
responses, which have been observed to be mostly against VP40 and NP [5]. Although it
is unclear what leads to a nominal or aberrant humoral response, it has been observed in
both humans and experimentally-infected primates that EBOV infection induces a
significant bystander apoptosis of lymphocytes [4,5,6,7,8].
Interestingly, the role of antibodies in mediating protection to EBOV is unclear.
Several studies have demonstrated that the passive transfer of GP-specific monoclonal
antibodies to mice, or hyperimmune equine IgG to guinea pigs and mice can protect
against EBOV challenge [9,10,11]. However, other studies have found no efficacy in
passive antibody transfer of polyclonal antibodies to guinea pigs or mice [12,13]. The
KZ52 antibody, a neutralizing monoclonal antibody isolated from a human survivor, can
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be administered to protect guinea pigs [14]. However, the passive transfer of KZ52
antibodies does not protect nonhuman primates [15]. And although one study has
reported efficacy of infusion of convalescent patient blood to EHF patients during an
outbreak, other factors may have played a role in the recovery of these patients and
similar studies in primate models have been unable to repeat this finding [16,17].
Furthermore, several vaccine studies in both mice and macaques have concluded that
cellular- not humoral- immunity is a correlate of vaccine protection against EBOV
[13,18,19].
In the present study, we examined the interaction of the KZ52 antibody with its
epitope on the main EBOV glycoprotein, GP. GP is actually the minor product of the
glycoprotein gene; the major product is a dimeric, secreted form (sGP) whose function
remains unclear [20,21]. Full-length, trimeric, membrane-bound GP results from
transcriptional editing of the glycoprotein gene by the viral polymerase [20,22]. This
form is expressed at the cell surface, is incorporated into the virion, and drives viral
attachment and membrane fusion [20]. GP is initially translated as a precursor (GP0),
which is then cleaved by furin within the Golgi into two subunits, a surface subunit, GP1
and a membrane-spanning subunit, GP2 [23]. These subunits remain covalently connected
through a single intermolecular cysteine bond [24]. During viral entry, GP1 is proteolyzed
by endosomal cathepsins, which removes the glycosylated glycan cap and mucin domains
and exposes the receptor-binding domain (RBD) [25,26,27,28].
Expression of GP has been shown to cause effects in cell culture on host surface
proteins similar to those observed during viral infection, and so is proposed to be an
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important determinant of viral pathogenesis [22,29,30,31]. GP expression in cultured
cells disrupts cell adhesion resulting in loss of cell-cell contacts as well as cell rounding
and loss of attachment to the culture substrate [29,31,32]. By flow cytometry, cells
expressing GP display dramatically lowered levels of various surface proteins, including
several members of the integrin family and MHC class I [31,32,33]. These effects of
EBOV GP are known to be caused by a highly glycosylated region in GP1, the mucin
domain [29,32,33]. In the previous chapters of this dissertation, we demonstrate that the
mucin domain of GP sterically shields affected surface proteins from antibody
recognition, giving the appearance of a loss of expression by surface staining flow
cytometry. Interestingly, we found that the GP1 subunit also shields the epitope for the
KZ52 antibody, preventing its binding to GP at the cell surface.
In the present study we analyze the requirements for the shielding of the KZ52
epitope by GP and hypothesize that such shielding may occur on the surface of viral
particles. We have found that the glycan cap seems to be necessary for blocking antibody
access to the KZ52 epitope at the cell surface. We further demonstrate that a form of GP
lacking this domain and the mucin domain shows greater antibody binding on
pseudoviral particles, although a modulation of neutralization was not observed. These
data impel further research into this model as a potential immune evasion mechanism by
EBOV.
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4.3

Materials and Methods

Plasmids, cell culture and transfections
For GP studies, cDNA encoding the membrane-anchored form of Zaire EBOV
GP (Mayinga strain, accession number U23187) was used. GP containing a deletion of
the mucin domain (GPΔmuc), amino acids 302-462 has been previously described [32].
For furin processed construct (primed GP), the amino acids VNAT at positions 203-206
were replaced with the amino acids RRKR. All constructs contain a C-terminal V5-His
tag and are cloned into the pCAGGS expression vector. For over-expression of furin,
cDNA encoding human furin was described previously, but was sub-cloned into the
pCDNA3.1 expression vector for use here [34].
293T cells were cultured in DMEM (Gibco) with 10% fetal bovine serum
(HyClone) and penicillin/streptomycin (Gibco) at 37 ºC with 5% CO2. For flow
cytometry and western blotting, 293T cells were plated in 6-well plates one day prior to
transfection. Cells were transiently transfected by Lipofectamine 2000 according to
manufacturer’s directions with 4 µg DNA per well. For pseudovirus production, 293T
cells were plated in 10 cm plates one day prior to transfection. Cells were then transfected
with varying amounts of DNA by calcium-phosphate precipitation; media was replaced 5
hours post transfection. For pseudovirion neutralization assay, cells were plated in
Biocoat 96-well plates (Becton & Dickinson) one day prior to infection. One hour prior
to infection, cells were replaced with fresh media.
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Cell lysates and western blotting
Transfected cells were removed by resuspension in the culturing media. Cells
were pelleted at 4 ºC for 3 minutes at 1300 x g. Pellets were resuspended in 1% Triton X100 buffer with complete protease inhibitor cocktail (Roche) for 5 minutes at room
temperature. Lysates were cleared by centrifugation at 4 ºC at 20,800 x g. 30 µl samples
were mixed with reducing SDS buffer, boiled for 5 minutes, and separated on a 4-15%
Criterion PAGE gel (Bio-Rad). Proteins were transferred to PVDF (Millipore) at a 400
mA constant current. Membranes were blocked in 5% milk in TBS. For detection of GP,
membranes were probed with rabbit polyclonal anti-GP sera which recognizes the GP1
subunit, in blocking buffer [35]. For detection of V5 epitopes, membranes were probed
with rabbit anti- V5 antibodies (Bethyl Labs), in blocking buffer. For detection of the
mucin domain, membranes were probed with the 13F6 mouse monoclonal antibody in
blocking buffer [11]. Proteins were detected with stabilized goat anti- mouse or rabbit
HRP conjugated antibodies (Pierce), in blocking buffer. For detection of the human KZ52
antibody, membranes were probed with anti- human HRP-conjugated antibodies (Jackson
ImmunoResearch Laboratories), in blocking buffer. Membranes were visualized with
SuperSignal Femto substrate (Pierce).

Flow cytometry
293T cells were detached from the plate 24 hours post transfection with PBS -/-,
0.5 mM EDTA and combined with floating cells in culture media. Cells were pelleted at
4 ºC at 250 x g, then resuspended in flow wash buffer (PBS -/- with 1% bovine calf
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serum and 0.05% NaAzide) and aliquoted for staining. For detection of EBOV GP, cells
were stained with the human MAb, KZ52 [36] and detected with FITC anti-human IgG
(PharMingen). For detection of β1 integrin, cells were stained with anti-human CD29 PECy5 conjugate (eBioscience); for detection of MHC1, cells were stained with anti- HLAABC PE-Cy5 conjugate (eBioscience). For fixation and permeabilization, cells were
resuspended in Cytofix/Cytoperm (BD Biosciences) for 20 minutes on ice, followed by
washing with Permwash (BD Biosciences). Antibodies where then diluted in Permwash
buffer. All staining was performed on ice, followed by washing. Live cell gates were
drawn based on forward and side scatter. For each sample, 10,000 events in the live cell
gate were collected and analyzed. Data were collected on a Becton Dickinson
FACSCalibur and analyzed using FlowJo software (Tree Star, Inc.).

Production of lentiviral luciferase pseudovirions
Human immunodeficiency virus (HIV) luciferase-encoding pseudotyped particles
were produced as previously described [28]. Briefly, 293T cells were transfected with 10
µg of a luciferase-encoding HIV plasmid (pNL-luc) and 10 µg of additional HIV GagPol-encoding plasmid (psPAX). The following amounts of plasmid were co-transfected
to pseudotype the indicated glycoproteins: 10-20 µg of GP, 8 µg of GPΔmuc, 20 µg of
primed GP or 6 µg of pCB6-VSV(G). Viral supernatants were collected 48 hours
posttransfection, and pre-cleared by centrifugation at 250 x g at 4 ºC for 2 minutes.
Supernatant was then filtered through a 0.45 µm syringe filter, then concentrated through
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a 20% sucrose cushion by ultracentrifugation at 28,000 rpm in an SW28 rotor for 2 hours
at 4°C. Pelleted virions were resuspended in PBS overnight at 4°C.

Pseudovirion and glycoprotein normalization
HIV pseudovirions were normalization using p24 levels. Relative glycoprotein
incorporation was determined using a V5 epitope tag on the GP2 C terminus. Fluorescent
western blot analysis was employed to quantify p24 and V5 as follows: For each sample,
15 µl of pseudovirions (in triplicate lanes) were mixed with reducing SDS buffer, boiled
for 5 minutes, and separated on a 4-15% Criterion PAGE gel (Bio-Rad). Proteins were
transferred to PVDF (Millipore) at a 400 mA constant current. Membranes were blocked
in 5% milk in TBS. p24 levels were probed with mouse anti- p24 monoclonal antibody
241-D (NIH AIDS Reagent Program); V5 levels were probed with rabbit anti- V5
polyclonal antibodies (Bethyl Labs). Anti- mouse IRDye800CW antibodies (1:5,000;
Rockland) and anti- rabbit Alexa Fluor 680 (1:10,000; Invitrogen) were then used to
detect p24 and V5, respectively. Blots were scanned using an Odyssey infrared imaging
system (LI-COR) and band intensities were quantified using LI-COR software. Triplicate
lane bands were averaged to give relative sample quantities, measured in relative
fluorescent units, RFUs. Average p24 RFUs were used to normalize across samples. For
evaluation of glycoprotein incorporation, the ratio of V5 to p24 RFUs were calculated so
that a higher quotient indicates better incorporation and a lower quotient indicates poorer
incorporation.
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Pseudovirion immunoprecipitation
Pseudovirions were diluted in eppendorf tubes in flow wash buffer (PBS -/- with
1% bovine calf serum and 0.05% NaAzide) or 1% NP40 buffer to a final volume of 350
µl and incubated with 3 µg of KZ52, mouse anti- V5 (Invitrogen), or mouse anti- HA
(12CA5, Roche) antibodies for 1 hour at 4 ºC, rocking. Antibodies were captured by
adding 12.5 µl Protein A Dynabeads (Invitrogen), pre-washed in the appropriate buffer,
and incubating for 2 hours at 4 ºC, rocking. Complexes were isolated using a MACS
separation magnet (Miltenyi Bioech) and washed twice with the appropriate buffer.
Samples were then analyzed by western blotting as described above.

Pseudovirion bound antibody analysis
Pseudovirions were diluted in flow wash and incubated with antibodies as
described above. Samples were then further diluted to 3.5 ml in PBS and layered above a
1.5 ml 20% sucrose cushion in Ultra-Clear centrifuge tubes (Beckman) and centrifuged in
a SW55 rotor at 54,000 rpm for 36 minutes at 4 ºC. Supernatants were decanted and
pelleted pseudovirions were resuspended in 1% Triton X-100 lysis buffer for 5 minutes at
room temperature. Protein A Dynabeads were then added and used for
immunoprecipitation as described above.

Pseudovirion neutralization
Samples were normalized for p24 levels. Pseudovirions were diluted in media
and mixed with serially-diluted KZ52 antibody, or media as a control, in a combined
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volume of 50 µl. Pseudovirion/antibody mixtures were incubated on ice for 20 minutes.
Pseudovirions were then added to cells for a combined volume of 100 µl. Indicated
antibody concentrations are relative to final combined 100 µl volume. All samples were
performed in triplicate. 48 hours after infection, supernatants were removed and cells
were lysed in 100 µl 0.5% Triton X-100 for 5 minutes at room temperature. 50 µl from
each well was then transferred to a 96-well black, solid bottom plate. 100 µl firefly
luciferase substrate (Promega) was added to each well and the plate was assayed on a
luminometer (Dynex / Thermo). Percent normalized infection values were calculated by
setting the relative luciferase values from the no antibody sample to 100%.
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4.4

Results

GP mucin and glycan cap domains can be proteolytically removed during secretion
We have previously demonstrated that EBOV GP from the highly-pathogenic
Zaire subtype sterically shields the epitopes of several host proteins at the cell surface, as
well as epitopes on GP itself (Figure 3-3). We have also shown that the mucin domain is
necessary and sufficient to shield these host proteins (Chapter 2). However, the critical
domain(s) on GP responsible for shielding the KZ52 epitope has not been elucidated.
Removal of the entire GP1 surface subunit restores KZ52 staining at the cell surface
(Figure 3-4), however, GP1 contains several domains: the mucin domain, glycan cap,
RBD-containing head region, and the GP1 base, which makes contacts with the KZ52
antibody (Figure 1-4 and [25]). The glycan cap contains 4 bulky N-linked glycosylation
sites that are positioned such that they could shield the RBD. Therefore, it was beneficial
to create a construct that lacked both the glycan cap and the mucin domain so that we
could evaluate the potential of this domain to shield epitopes on GP. Although genetic
deletion of the mucin domain is viable, genetic deletion of both the mucin domain and the
glycan cap does not result in properly folded protein (P.B., unpublished observation).
Therefore, we created a GP construct in which amino acid residues from 203-206 were
mutated to a recognition sequence for the cellular protein convertase, furin (Figure 4-1
A). This sequence is located within a disordered loop in GP, and is 4 residues
downstream of the primary site of cathepsin cleavage during entry, which removes the
mucin and glycan cap domains [25,27]. When this construct is expressed in cells, GP is
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Figure 4-1
Characterization of primed GP construct. (A) Diagram of EBOV GP
domains, modified from [25]. Primed GP construct was created by mutating amino acid
resides 203-206 to RRKR. Construct also encodes a C-terminal V5-His tag. (B) GP and
primed GP expression. 293T cells were transfected with plasmid encoding GP or primed
GP. 24 h post transfection, cells were lysed in Triton X-100, resolved by SDS-PAGE
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under reducing conditions, transferred to PVDF, and blotted for GP using polyclonal
rabbit anti-GP antibodies (left blot) or polyclonal rabbit anti- V5 antibodies (right blot).
(C) Primed GP construct was expressed alone or co-transfected with increasing
concentrations of plasmid encoding human furin. Cell lysates were harvested and
resolved by SDS-PAGE and blotted for GP using rabbit polyclonal antibodies as above.
(D) Incorporation of GP and primed GP into lentiviral pseudovirions. Bald pseudovirions
or pseudovirions bearing GP or primed GP were produced and purified as described in
materials and methods. Aliquots were then resolved by SDS-PAGE and blotted for GP
using rabbit polyclonal antibodies as above. (E) The glycan cap and mucin domain are
removed from pseudovirions bearing primed GP. Pseudovirions bearing VSV G, EBOV
GP, or primed GP were produced and purified as above. Aliquots were then resolved by
SDS-PAGE and blotted for the mucin domain using the 13F6 antibody, for GP2 using
anti- V5 antibodies, and for the lentiviral capsid using anti- p24 antibodies. (F) Primed
GP does not shield surface proteins. 293T cells were transfected with empty pCAGGS
(vector) or vector encoding GP or primed GP. Floating and adherent cells were harvested
24 h after transfection, pooled, and stained for GP using the KZ52 antibody, followed by
FITC-labeled secondary antibodies, and co-stained for β1 integrin or MHC1 with PE-Cy5
conjugated monoclonal antibodies and assayed by flow cytometry.
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processed by endogenous furin to produce an approximately 24 kDa fragment that
corresponds to GP1 that lacks the mucin domain and glycan cap and has been termed,
primed GP (Figure 4-1 B and [37]). The primed GP construct is well-expressed and
stable in cells, compared to wild-type GP, however, processing from the mature form of
GP to the primed form by endogenous furin is incomplete (Figure 4-1 B, left blot). To
increase processing, furin was over-expressed with the primed GP construct,which
resulted in nearly complete processing of mature GP to primed GP (Figure 4-1 C).
Primed GP was well incorporated into HIV pseudovirions, in which no mature,
unprocessed GP could be detected by western blot (Figure 1-4 D). Similarly, antibodies
recognizing the mucin domain react with pseudovirions bearing full-length GP but not
primed GP, indicating this domain has been removed (Figure 1-4 E).

Primed GP does not shield epitopes at the cell surface
In the Primed GP construct, the mucin domain and glycan cap have been cleaved
from the full-length protein. If these domains are physically separated from the remaining
GP1 domains at the cell surface, primed should not be capable of shielding host surface
proteins. To evaluate this, we expressed primed GP in 293T cells and surface stained
them for β1 integrin and major histocompatibility complex class 1 (MHC1) and for GP.
As shown in Figure 4-1 F, GP causes dramatic shielding of β1 and MHC1, resulting of
cells that stain dimly for these proteins, while primed GP does not display this effect.
These data indicate that the mucin and glycan cap domains have been removed from their
normal position in GP1.
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Figure 4-2
Primed GP does not shield the KZ52 epitope at the cell surface. (A)
293T cells were transfected with empty pCAGGS (vector) or vector encoding GP,
GPΔmuc, or primed GP. Floating and adherent cells were harvested 24 h after
transfection, pooled, and stained for GP using the KZ52 antibody, followed by FITClabeled secondary antibodies and assayed by flow cytometry. (B) To evaluate each form
of GP’s ability to shield the KZ52 epitope, samples from (A) were fixed and
permeabilized in parallel, then stained for KZ52 and assayed by flow cytometry. To make
a direct comparison between surface stained and fixed/permeabilized samples, FL-1
channel voltages were set to overlap each other using the empty vector samples (left-most
plot).
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We next wanted to address whether the glycan cap played a role in shielding the
KZ52 epitope at the cell surface. 293T cells were transfected with plasmid encoding GP,
GP lacking the mucin domain (GPΔmuc), or primed GP. 24 hours after transfection, cells
were harvested and stained for GP with the KZ52 antibody and assayed by flow
cytometry (Figure 4-2 A). As we have previously shown (Figure 3-3), GP shields this
epitope at the cell surface. The mucin domain seems to be dispensable for this effect,
because GPΔmuc shows similar levels of surface staining for KZ52 as GP. Interestingly,
primed GP displays much higher levels of staining, with the majority of cells showing
uniformly bright staining. Because the difference between GPΔmuc and primed GP is the
presence or absence of the glycan cap, we conclude that this domain is critical for the
shielding of the KZ52 epitope at the cell surface.
To further evaluate the role of the glycan cap in shielding epitopes on GP, we
attempted to rescue staining of the occluded KZ52 epitope. We have previously shown
that treatment of GP-expressing cells with saponin will rescue KZ52 staining (Figure 32). This effect appears to be a result of saponin binding to cholesterol at the plasma
membrane, and not due to the fact that the cells become permeabilized (J.R.F.,
unpublished observations). Therefore, we can gauge the ability of each GP construct to
shield the KZ52 epitope by pre-treating cells with a saponin solution. This treatment
dramatically increases staining in cells expressing GP or GPΔmuc, indicating that these
constructs had shielded the KZ52 epitope (Figure 4-2 B). In contrast, saponin treatment
does not significantly alter the high level of KZ52 staining in cells expressing primed GP.
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These data indicate that primed GP does not shield the KZ52 epitope and further support
the conclusion that the glycan cap is necessary for this shielding.

EBOV GP imposes steric constraints on lentiviral pseudovirions
Because full-length GP is capable of shielding the KZ52 epitope at the cell
surface, we hypothesized there may be comparable steric occlusion on viral particles. For
these experiments, primed GP was used as a control because it is unable to sterically
occlude epitopes at the cell surface, as previously demonstrated. To address this question,
we performed immunoprecipitations (IPs) of intact pseudovirion preparations diluted in a
PBS-based buffer by incubating pseudovirions with KZ52 then immunoprecipitating
antibody-particle complexes with protein A. It had been previously reported that KZ52
antibodies could IP intact pseudovirions bearing GP, but not particles that had been in
vitro treated with cathepsin L to produce primed GP [38]. In contrast to that report, we
found that KZ52 was not able to immunoprecipitate particles bearing GP, whereas KZ52
particles bearing primed GP were effectively recognized (Figure 4-3 A). These IPs had
extremely low background, as judged by IP with control anti- HA antibodies. Also, the
pseudovirion preparations used here contained only a small fraction of ruptured particles,
as judged by IP with anti- V5 antibodies, which will only IP GP that is not protected by a
viral lipid envelope. Therefore, it appeares that the mucin domain and glycan cap of GP
prevent the necessary protein A-antibody-virion interactions from occurring. This is
further supported by the fact that such interactions could be restored when particles were
lysed and
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Figure 4-3
Steric occlusion by GP on lentiviral pseudovirions. (A) Lentiviral
pseudovirions bearing GP or primed GP were incubated with KZ52, anti- V5, or anti- HA
antibodies in PBS buffer, or incubated with KZ52 antibodies in NP40 buffer. Dynabeads
conjugated to protein A were then added to IP pseudovirions. Beads were boiled in
reducing buffer, resolved by SDS-PAGE, transferred to PVDF, and blotted for GP using
polyclonal rabbit anti-GP antibodies (top panel) or polyclonal rabbit anti- V5 antibodies
(bottom panel). The anti- V5 IP indicates the amount of disrupted particles in each
sample; the anti- HA IP indicates non-specific binding. (B) To determine the amount of
antibody bound to GP or primed GP pseudovirions, KZ52, V5, or HA antibodies were
bound to particles in PBS buffer, then purified away from unbound antibodies through a
20% sucrose cushion. Pelleted particles were resuspended in Triton-X100 lysis buffer,
then immunoprecipitated and resolved by SDS-PAGE as described above. Membranes
were probed for GP with polyclonal rabbit anti-GP antibodies (top panel), and probed for
bound KZ52 antibody with anti- human IgG antibodies (bottom panel). For pseudovirion
preparations used in this experiment, primed GP was found to incorporate at levels 70%
of that of GP.
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immunoprecipitated in a buffer containing NP40 detergent (Figure 4-3 A). These results
are consistent regardless of whether one visualizes the GP1 (top panel) or GP2 (bottom
panel) subunits.
Although we have shown that GP prevents the IP of intact virions using the KZ52
antibody, this experiment does not address whether GP prevents the KZ52 antibody from
binding, or whether it prevents protein A from interacting with bound antibody. To
further probe this question, we performed a similar experiment, but first purified intact
pseudovirions away from unbound antibody. These re-purified particles were then lysed
and IPs were carried out in buffer containing detergent. As Figure 4-3 B shows, the
amount of bound KZ52 antibody is greater on particles bearing primed GP, compared to
particles bearing full-length GP (bottom panel). This bound antibody was capable of
immunoprecipitating both primed GP and full-length GP once the particles were lysed
(top panel). These data suggest that steric occlusion by GP may serve to interfere with
antibody binding. Additionally, because bound KZ52 can be detected on GP-bearing
pseudovirions, shielding by GP is also likely also preventing access of protein A to bound
antibodies.

Impact of GP shielding on neutralization by KZ52
We have observed that antibody access to lentiviral pseudotyped particles may be
limited by the mucin and glycan cap domains on GP. Therefore, we wanted to assess
whether this impacted the amount of antibody required to neutralize these pseudovirions.
KZ52 has been shown to neutralize replicating EBOV with an IC50 of 0.3 µg/ml as well
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Figure 4-4
Neutralization of lentiviral pseudovirions by the KZ52 antibody.
Lentiviral pseudotyped particles encoding luciferase and bearing VSV G, GP and
GPΔmuc (A) or primed GP (B) glycoproteins were incubated with KZ52 antibodies over
a range of concentrations then applied to 293T cells. 48 h after infection, supernatants
were removed, cells were lysed in Triton-X100 and firefly luciferase substrate was added.
Luciferase activity was measured by luminometer. All samples were performed in
triplicate and were normalized to infection of pseudovirions incubated without antibody.
Data shown are representative of at least two independent experiments. For pseudovirions
preparations used in this experiment, GPΔmuc was incorporated at levels 105% of that of
GP; primed GP was incorporated at levels 98% of that of GP.
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as lentiviral pseudotypes bearing GP; however, a recent report found that cathepsin Lprocessed pseudotypes bearing GP could not be neutralized by KZ52 [36,38]. We
compared the neutralization of pseudotypes bearing GP or GPΔmuc (Figure 4-4 A) and
GP or primed GP (Figure 4-4 B). KZ52 efficiently neutralized pseudotypes bearing all
three forms of the EBOV glycoprotein, but not those bearing VSV G. The IC50 values for
these neutralization profiles were all approximately 0.3 µg/ml, comparable to that
observed with EBOV. Therefore, we conclude that the observed steric occlusion by the
mucin domain and glycan cap of GP does not impact the neutralization sensitivity of HIV
pseudovirions.
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4.5

Discussion
In this study we have examined the ability of the highly-glycosylated mucin and

glycan cap domains in GP to modulate access to the neutralizing epitope bound by the
KZ52 antibody. Our hypothesis that the glycan cap might play a critical role in providing
steric occlusion necessitated the creation of a mutant form of GP lacking this domain. In
creating the primed GP construct, we are able to transport a form of GP to the cell surface
that resembles the structure of GP after it is processed by endosomal cathepsins during
entry (for which the term, primed GP, was first coined) [25,27,37]. Because this primed
GP can be easily incorporated into budding pseudotyped particles (Figure 4-1 D), this
construct should be highly useful in the study of viral entry. It presumably adopts the
same confirmation as cathepsin-processed GP, but obviates the need for in vitro cathepsin
treatment, which can be heterogeneous and is prone to over-processing. A chimeric GPFc protein that encompasses the region found in primed GP has been produced in soluble
monomeric form and has been shown to bind to the surface of susceptible cells [37]. In
contrast, the primed GP construct described here is trimeric because it is initially
synthesized and folded as full-length GP. If the quaternary structure of trimeric GP is
important for receptor engagement or structural rearrangement, this primed GP construct
may prove useful in EBOV entry studies. This idea is conceptually supported by the
crystal structure of GP, which shows that GP2 subunits interact with GP1 subunits on
neighboring monomers [25].
It is interesting to note that this study has produced results that would seem to
contradict a previously published study by Shedlock and colleagues in two particular
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areas [38]. In their study, they examined the ability of the KZ52 antibody to bind and IP
intact pseudovirions bearing GP and cathepsin L-processed GP; unprocessed GP was able
to be immunoprecipitated, while cathepsin L-processed GP was not. However, in Figure
4-3 A, we show evidence that GP is unable to be immunoprecipitated unless detergent is
added to the IP to solubilize the glycoproteins. It is possible that our full-length GP is
incorporated to higher levels in our pseudovirion preparations than in the previous study,
giving rise to our conclusion that GP provides a steric shield on particles. This may not
be true, however, as the amount of GP-encoding plasmid was actually scaled back from
our usual preparation to better match the incorporation level of primed GP. The other
discrepancy between our data and the study by Shedlock et al., is their report that
pseudovirions bearing cathepsin L-processed GP can neither be immunoprecipitated nor
neutralized by the KZ52 antibody. This finding is somewhat surprising because cathepsin
processing does not directly involve the residues that form the KZ52 epitope [25,27]. Our
data in figures 4-3 A and 4-4 B clearly demonstrate that primed GP, which should
faithfully mimic the cathepsin-processed form, is readily immunoprecipitated and
neutralized by KZ52. One possible explanation then, is that the primed GP construct
described here stability preserves the KZ52 epitope, while cathepsin treatment of GP
yields a more unstable primed form. This could occur by over-processing with cathepsin
L, which can further degrade the primed GP form (P.B. and R. Kaletsky, unpublished
observation), or could result from the fact that our construct is cleaved by furin at residue
206, while cathepsins process GP at residue 202 [27]. Perhaps these extra 4 amino acids
serve to further stabilize the KZ52 epitope.
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In Figures 4-2 and 4-3, we have endeavored to demonstrate that the mucin domain
and glycan cap are capable of imposing steric constraints on the KZ52 epitope, both at
the cell surface and on the virion surface. Interestingly, we show that by removing the
glycan cap, through expression of primed GP, KZ52 staining is restored to high levels
that are comparable to the rescue seen after fixation and permeabilization of cells
expressing GP or GPΔmuc (Figure 4-2). Although these data indicate that the glycan cap
is critical to the shielding of the KZ52 epitope at the cell surface, the mechanism by
which this domain promotes shielding is unknown. The glycan cap contains 4 N-linked
sugar moieties, and we have shown that N-liked glycosylation plays a role in shielding
surface epitopes (Figure 3-5). However, the glycan cap sits on top of the GP head domain
in a position unlikely to directly occlude the KZ52 epitope [25]. The glycan cap might
instead serve to maintain a certain density or arrangement of GP trimers at the cell
surface, which might lead to occlusion of the KZ52 epitope.
Additionally, these studies demonstrate that the presence of the mucin and glycan
cap domains partially prevent binding of KZ52 antibodies to the surface of pseudovirions
and significantly prevent their immunoprecipitation (Figure 4-3). These data suggest that
our model of a GP-mediated glycan shield at the cell surface may also apply to the virion
surface. This concept may be best described for HIV, in which a similar glycan shield
model has been described [39]. Glycosylation sites on HIV envelope have been observed
to mutate in response to antibody pressure, and their removal has been shown to increase
antibody sensitivity [39,40]. EBOV GP glycosylation may act in a similar manner to
modulate antibody binding (Figure 4-3 B); however, our neutralization data have not
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revealed any difference in KZ52 sensitivity between forms of GP that possess or lack the
ability to shield. It is possible that the amount of antibody that is able to bind GP
pseudovirions is fully sufficient to neutralize particles so that any increase in antibody
opsonization does not impact neutralization. However, it is also important to note that
these assays have been performed using lentiviral pseudotyped particles, which are
relatively easy to produce and assay for infectivity, but may not accurately reflect the
arrangement or density of glycoprotein trimers on the surface of filoviral particles. For a
more biologically relevant comparison, neutralization assays should be performed using
filamentous virus-like particles.
The ability of GP to shield the virion surface could impact pathogenesis in several
ways. The modulation of antibody binding to neutralizing epitopes could prolong the
clearance of virus by the humoral response. This strategy could explain, in part, the
observations that the infusion of convalescent blood or passive transfer of antibodiesincluding the KZ52 antibody studied here- can fail to protect experimentally infected
animals [12,13,15,16]. Virion shielding might also be critical in the natural animal
reservoir, proposed to be several species of fruit bats, in which EBOV may need to
successfully evade the adaptive immune response over a long time [41]. Additionally, the
ability of GP to shield the virion surface could impact the ability of the innate immune
response to clear the virus. Complement-mediated neutralization can occur with
antibodies through the classical pathway, without antibody opsonization through the
alternative pathway, or through interactions with mannose binding lectin (MBL) [42,43].
Indeed, the glycans on GP have been found to contain significant amounts of mannose,
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and one study has reported that GP-bearing pseudotypes can be neutralized by
complement, in part through the MBL pathway [44,45,46]. However, it is possible that
the ability to sterically shield the virion surface provides partial protection from
complement. It may be interesting to compare the effects of complement-mediated
neutralization on pseudotypes bearing GP or primed GP. Taken together, these data
indicate that highly-glycosylated domains within GP can place steric constraints on the
cell and virion surface, and suggest further study should be conducted into the effects this
may have on the recognition and neutralization of EBOV by the immune system.
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CHAPTER 5 − GENERAL DISCUSSION AND FUTURE DIRECTIONS
5.1

Summary of major conclusions
This dissertation contains three chapters exploring the interactions of the Ebola

virus (EBOV) glycoprotein (GP) with host cellular and immune responses. In chapter 2
we examined several requirements necessary for GP to induce cytopathology in cells.
The most striking conclusion from this chapter is the demonstration that the mucin
domain of GP can cause cytopathology when expressed within the context of the
irrelevant avian glycoprotein, Tva (Figure 2-1 E and Figure 2-2). The mucin domain
potently induced cell rounding, detachment, and the loss of surface staining by flow
cytometry in a manner that was nearly indistinguishable from the full-length GP. The
mucin domain was previously known to be necessary for these effects, as genetic deletion
of this domain abolished GP-induced cytopathology [1,2,3]. However, the determination
that this domain was not only necessary, but also sufficient to cause cytopathology
represented a quantum step in our understanding of the mechanism of GP-mediated
cytopathology. Chapter 2 also provided data indicating that GP was acting in a post-ER
step of the secretory pathway and was not acting through a dynamin-dependent pathway.
These were incremental advances in our understanding of the biology of cytopathology,
but they helped us to focus our attention on the plasma membrane as playing a critical
role in this phenomenon. These findings, especially the fact that the mucin domain could
be displayed at the cell surface on a heterologous protein and cause cytopathology, lead
us to consider a model of steric hindrance, which is the focus of chapter 3.
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Chapter 3 is an in-depth study of the cellular mechanism of EBOV GP-mediated
cytopathology. This chapter addresses two basic observations, and then hypothesizes a
single model to account for both. The first is the observation that, in cells displaying full
detachment from the culture dish, surface staining for GP was dim by flow cytometry
(Figure 3-1 B). This was counter-intuitive because such drastic cytopathology seemed
likely to occur in cells with the highest level of GP expression. Therefore, we proposed
the model that the epitope used in that analysis was occluded from antibody access due to
its position at the base of the structure of GP, buried under the mucin domain. We went
on to demonstrate that different epitopes on GP displayed different levels of staining by
flow cytometry, depending on their position relative to the mucin domain and glycan cap.
These experiments served as a proof of concept for our shielding model. We then tested
this model in reference to the second observation, which is that by flow cytometry GP
appeared to down-modulate host surface proteins. The critical experiment in chapter 3 is
found in Figure 3-4 D, in which DTT was used to strip GP1 subunits off the cell surface.
The result of this treatment was the uncovering of previously-shielded epitopes and was
direct evidence that GP was occluding surface proteins at the plasma membrane. We then
went on to test the next logical hypothesis about the ability of GP to shield at the cell
surface: we hypothesized and found that glycosylation on GP played a significant role in
steric shielding. Our approach to analyzing surface glycans centered on enzymatic
removal of sugars from the cells surface with glycosidases, which again revealed
previously-shielded surface proteins (Figure 3-5). The strength of the approaches taken
here lie in the fact that cells in which cytopathology had already occurred could be
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manipulated to show that surface proteins that had been shielded could be uncovered.
These experiments strongly supported our model that GP, by virtue of the highlyglycosylated mucin domain, sterically occluded surface epitopes from antibody
recognition. This model also explained our data from chapter 2, suggesting that the mucin
domain could provide its steric shield even when expressed on the Tva protein.
The third conceptual study in this dissertation is encompassed by the experiments
at the end of chapter 3 and in chapter 4. Here we wanted to further investigate the
consequences of steric shielding by GP. One consequence, which had been observed by
several previous groups, is that the shielding of integrins had the effect of disrupting
adhesion [1,2,3,4,5,6]. Given the observation that major histocompatibility complex class
1 (MHC1) was also shielded by GP, we asked whether this had the functional outcome of
disrupting antigen presentation. This hypothesis was supported by our experiments using
CD8 T cells that are specifically activated by a tumor cell line displaying an antigenic
peptide from the human immunodeficiency virus (HIV) (Figure 3-7). The activation of
CD8 T cells was blocked on cells expressing GP, demonstrating another functional
consequence of GP-mediated cytopathology.
Finally, we wanted to ask whether our model of shielding by GP applied not just
to the cell surface, but to the surface of the virion as well. Chapter 4 begins to address this
hypothesis and describes two interesting findings. The first is that the glycan cap- not the
mucin domain- seems to be the critical domain in shielding the KZ52 antibody from the
cell surface. This was somewhat surprising, as our previous studies found the mucin
domain to be necessary and sufficient to shield host surface epitopes (Chapter 2). We
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then used this finding to assess potential shielding of this antibody using a form of GP
that lacks both the mucin domain and the glycan cap. By removing both of these domains
implicated in shielding, we found evidence that GP places steric constraints on the
surface of retroviral pseudovirions, which blocks immunoprecipitation (Figure 4-3). Our
study went on to suggest that shielding by GP partially prevents the binding of KZ52
antibodies, but failed to find an impact on neutralization sensitivity.

5.2

Relationship of this work to previous studies
The studies presented here describe a novel mechanism for GP-mediated

cytopathology that had not been previously considered. In fact, previous studies had
implicated other factors in this phenomenon. First, a study by Sullivan and colleagues
reported that down-regulation of surface proteins was dependent on the GTPase, dynamin
[2]. This makes some conceptual sense because many surface proteins, including β1
integrin, undergo dynamin-dependent endocytosis; although, natural endocytosis of
MHC1 is dynamin-independent [7,8,9]. We have directly addressed this report by
repeating the experiments conducted by Sullivan et al., but found that dynamin had no
effect on GP-mediated cytopathology (Figure 2-5). It is our opinion that previous
experiments using dominant-negative (DN) dynamin were misinterpreted, due to uneven
transfection levels between samples, which gave the appearance of fewer cells showing
GP-mediated cytopathology in samples containing DN dynamin.
A second study investigating the mechanism of GP-mediated cytopathology
found that the extracellular signal-regulated kinases types 1 and 2 (ERK 1/2) pathway
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was important for the loss of host protein surface staining by flow cytometry [10]. This
group presents compelling data that expression of the mucin domain decreases the
phosphorylation of ERK2. In contrast, another report had found that Ebola virus-like
particles (VLPs) activated the ERK pathway, and that this activation was dependent on
the mucin domain [11]. Although the interactions between GP and the ERK pathway may
be complex, and GP-dependent signaling likely occurs, the initial ERK investigation
found that loss of staining by flow cytometry could be enhanced by ERK2 knockdown or
reversed by the over expression of constitutively-active ERK2. Again, it is our opinion
that these experiments were misinterpreted due to uneven transfection levels among
samples.
The issue of signaling raises an important concern when studying GP-mediated
cytopathology. Loss of adhesion and cellular detachment may have profound effects on
cells that may relate more to the fact that the cells have detached than to the fact that GP
is expressed. For example, it has been reported that GP-induced detachment of primary
human cardiac microvascular endothelial cells results in apoptotic cell death [12]. This
anchorage-dependent apoptosis, or anoikis, likely results from “outside-in” signaling by
integrins through the phosphoinositide-3 kinase/AKT and other pathways to begin
programmed cell death [13,14,15]. Additionally, upon detachment, integrin signaling at
focal adhesions is lost, leading to the inactivation of focal adhesion kinase and the
subsequent loss of ERK signaling [16]. This likely explains the previous finding that GP
leads to loss of ERK2 activation, and would indicated that GP and ERK interactions are
only indirect [10]. Interestingly, different cell types have different dependences on
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anchorage for survival. A previous report from our group found that 293T cells
transiently expressing GP readily detached from the culture substrate, but remained
viable and regained adherence after additional culturing [1]. Taken together, these studies
highlight the need for careful consideration when examining the biology of detached cells
from adherent lines.
Another area of concern when studying GP-mediated cytopathology is the relative
expression level of GP achieved during transient expression compared to GP expression
during EBOV infection. It is possible or even likely that GP levels produced during
infection can be exceeded by over-expression systems. Moreover, we have observed that
GP-induced epitope shielding occurs only when GP expression reaches a certain
threshold (discussed in section 2.5), and others have reported that when GP expression is
driven by less active vectors, cytopathology is not observed [17]. Is it possible, then, that
the phenomenon of GP-mediated cytopathology is simply an artifact of over-expression?
Two reports have addressed this issue directly. In the first, 293T cells were infected with
EBOV; rounded and floating cells were observed at significant levels at 24 and 48 hours
post infection, and loss of integrin and MHC1 staining was observed by 48 hours [17].
The second study compared GP expression levels from an adenoviral expression system
to EBOV infection in human umbilical vein endothelial cells, both of which were found
to induce cell rounding. This report determined that GP expression levels were equivalent
by western blot [3]. These studies indicate that GP-mediated cytopathology occurs during
EBOV infection and that GP expression does not have to be driven to non-physiological
levels to study these effects. Although the studies in this dissertation were not repeated
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using live EBOV, we have used both an Adenoviral expression system and mammalian
expression vectors at carefully titrated levels to guard against overt over-expression.
The studies presented in this dissertation benefited greatly from the determination
of the crystal structure of the EBOV GP by the Saphire lab, which was published as our
work was ongoing [18]. Our hypothesis that the mucin domain and glycan cap might
provide a steric shield to nearby epitopes is conceptually supported by the position and
size of these domains. The co-crystallization of GP with the KZ52 Fab further supports
our model, because the position of this epitope is demonstrated to be beneath the heavilyglycosylated domains of GP. The mucin domain was genetically deleted in the construct
used to determine the structure; however, its general position was modeled (Figure 1-4).
Of note, the Saphire lab recently presented a low-resolution structure of the mucin
domain within soluble, trimeric GP, determined by small-angle X-ray scattering [19].
This structure indicates that the mucin domain extends up and out to the side of the
chalice-structured globular core, again supporting the concept that this domain could
provide steric shielding to nearby proteins.
Our model of steric hindrance by GP at the cell surface is additionally supported
by a recent study that compared surface staining of cells expressing GP using a panel of
anti- GP monoclonal antibodies [20]. This study concluded that differences in GP surface
staining were due to masking by GP and that this likely applied to other host surface
proteins. This study proposes an identical model of steric occlusion to the one presented
here, but their evidence is indirect. They do not directly test their model by mapping the
epitopes of their monoclonal antibodies to show that epitope shielding occurs relative to
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the highly-glycosylated regions. They use immunofluorescence and biochemical
membrane fractionation to show that surface levels of affected host proteins are
unchanged by GP - a finding that is highly suggestive of shielding - but do not provide
direct evidence of the model by uncovering previously-shielded epitopes, as we have
done in these studies.
One interesting product of these studies is the development of our primed GP
construct. Primed GP mimics the cathepsin processing that occurs during viral entry to
expose the receptor-binding domain (RBD) and allow for fusion [21,22,23,24]. Because
this is a critical step in the EBOV replication cycle, we have endeavored to characterize
primed GP to demonstrate its potential utility as tool for the study of EBOV entry (Figure
4-1). Therefore, it was concerning that Shedlock et al., found that cathepsin L-processed
GP could not longer be immunoprecipitated by the KZ52 antibody and pseudovirions
bearing cathepsin L-processed GP could not be neutralized by KZ52 [25]. This disagreed
with our findings that primed GP-bearing pseudovirions could be immunoprecipitated
and neutralized by KZ52 (Figures 4-3 and 4-4) and calls into question our claim that our
primed GP construct accurately reflects the structure of cathepsin-processed GP. As
discussed at length in section 4.5, in vitro cathepsin treatment may result in a less stable
form of GP that more readily undergoes further conformational rearrangements, which
would likely destroy the KZ52 epitope. Alternatively, cathepsin could be proteolytically
cleaving at a non-canonical site other than in the disordered loop that connects the glycan
cap to the head domain, which would not be reproduced by our primed GP construct.
This seems unlikely though, as an in-depth biochemical analysis of the GP products of
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cathepsin L processing identified the disordered loop as the only region of proteolysis
[23]. Furthermore, that report also found by surface plasmon resonance that the KZ52
antibody could bind soluble cathepsin-processed GP. In separate studies not germane to
this dissertation, we have preliminary data suggesting that primed GP also mimics the
increased binding and infectivity associated with in vitro cathepsin processing of GP
[24,26]. Therefore, we re-assert our claim that our primed GP construct accurately
reflects the processing of GP by cathepsin L, and that this construct should be of use in
the study of EBOV entry.

5.3

Role of GP-mediated cytopathology in EBOV pathogenesis
One major focus of this dissertation was to explore the functional consequences of

steric occlusion by GP. We have approached this topic from two angles: the shielding of
host surface proteins and the shielding of neutralizing epitopes on GP. It has been
appreciated by many groups that GP disrupts cell adhesion [1,2,3,4,5,6]. The fact that the
mucin domain is necessary and sufficient for this effect is not entirely surprising, as
cellular mucin proteins have long been known to be potent modulators of adhesion
through a similar mechanism of steric hindrance [27,28,29,30,31]. However, we also
noted that work on mucin proteins in the field of cancer biology has demonstrated that
cellular mucin proteins may also act to protect tumor cells from recognition by the
immune system [30,32,33]. One particularly intriguing report proposed a model of steric
shielding of the cell surface by Muc4, which would then prevent antibody and cytotoxic
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lymphocyte recognition of a cancerous cell [32]. Because we have also demonstrated
potent shielding of MHC1, we investigated the role of shielding in blocking interactions
with cytotoxic T cells (Figure 3-7). Our findings suggest that GP expression could protect
infected target cells from cellular immune surveillance in a similar manner to that
observed in mucin-expressing cancer cells. It is unknown whether this mechanism occurs
during EBOV infection. One could argue that because EBOV induces bystander
apoptosis of lymphocytes, an adaptive immune response is not an important factor that
has to be directly avoided during infection [34,35,36]. However, these observations are
specific to humans and non-human primates, which are non-natural hosts for EBOV. In
the natural host to EBOV, possibly fruit bats, the virus may have established an interplay
with the immune response in which it is necessary to avoid the killing of infected cells by
cytotoxic lymphocytes. Additionally, the disruption of MHC and other cellular adhesion
molecules may have the functional consequence of preventing professional antigen
presenting cells (APCs) from trafficking or properly stimulating lymphocytes. It is known
that monocytes and dendritic cells are early targets of infection and that these cells are
functionally compromised by EBOV infection [37,38,39,40]. While the active
suppression of the interferon response by EBOV VP24 and VP35 plays a likely role in
disrupting APCs’ effector functions, GP-mediated disruption of surface protein function
may further compromise their activities. Indeed, we have previously shown that PECAM1, a cell-adhesion molecule critical for leukocyte diapedesis, is shielded by GP in
HUVEC cells [1].
The second aspect of GP-mediated cytopathology is the ability to shield
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neutralizing epitopes on GP. From this observation, we designed experiments to test
whether shielding of the neutralizing KZ52 epitope would affect pseudovirion
neutralization (Figure 4-4). Despite our inability to observe such an effect using lentiviral
pseudovirions, we have observed that GP places steric constraints on these particles that
may prevent antibody binding (Figure 4-3). There is also reason to believe that the
glycosylated regions on GP may impact the immune response to EBOV virions. Indirect
evidence for this theory can be found in a study in which mice were vaccinated with fulllength or cathepsin-processed GP [23]. The authors found that sera from the cathepsintreated GP samples was 3-fold better at neutralizing GP-bearing lentiviral pseudovirions.
This suggests that the mucin domain and glycan cap are partially preventing the immune
response from making antibodies to the most potently neutralizing epitopes. It follows,
then, that GP lacking these domains might be more easily neutralized during infection.
This model is reminiscent of one proposed for HIV, in which N-linked glycans on the
envelope protein (Env) serve to protect critical components, including the CD4 receptorbinding domain, from antibody pressure [41]. Indeed, current HIV vaccination strategies
involve the modulation of Env glycosylation sites to illicit more protective immune
responses [42,43]. Here again, it is likely that the effect of protection of EBOV from
neutralizing antibodies may be more vital in the natural host to EBOV, in which the virus
may persist for long enough to encounter pressure from a humoral immune response.
Interestingly, it has been reported that antibody responses from human survivors of Ebola
hemorrhagic fever were primarily directed against the VP40 protein and the
nucleoprotein [34]. It seems likely, then, that steric shielding can occur on EBOV
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particles, but the contribution of this mechanism on pathogenesis needs to be further
characterized.
5.4

Future directions
The studies in this dissertation have elucidated the cellular mechanism of GP-

mediated cytopathology. However, significant questions are raised by this work that
remain to be addressed. Although our model of steric shielding at the plasma membrane
is well supported by the studies in chapter 3, the observation of a threshold requirement
for GP to shield surface epitopes could be further explored. It is clear from our work and
that of other groups that low levels of GP expression do not cause cell detachment or loss
of surface staining by flow cytometry (Figure 2-4 and [17]). What changes occur in cells
that have just reached the threshold of GP expression necessary to cause cytopathology?
One possibility is that surface GP re-localizes into specific microdomains, such as lipid
rafts, at a certain surface density. GP has been suggested to target to lipid rafts during
infection; however, in-depth studies have not been conducted [44]. Additionally, our
finding that the GP mucin domain causes cytopathology from the transmembraneanchored, but not GPI-anchored form of Tva suggests the importance of surface
microdomains (Figure 2-2). It would be feasible to stain cells for GP, and then sort cells
by flow cytometry that do or do not display the required GP expression for
cytopathology. These populations could then be fractionated on density gradients to
query whether GP has localized into low-density fractions containing lipid raft
components.
Another intriguing question left unanswered by these studies is the stoichiometric
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requirements for GP-mediated cytopathology. For example, does it take one GP trimer to
effectively shield an integrin molecule or does it take 5 or 10 trimers? This question
could potentially be answered using quantitative flow cytometry to measure and compare
the number of surface molecules of GP to that of an affected host protein. This requires
identifying antibodies whose epitopes are not shielded by GP so that an accurate
comparison would be made. We and other groups have shown that such un-shielded
epitopes can be found on GP; however, our analysis of several MHC1 epitopes suggests
this could be more challenging for host surface proteins (Figures 3-3, 3-6 and [20]).
Our observation that MHC1 is functionally shielded by GP so that they cannot be
recognized by CD8 T cell receptors raises the possibility that EBOV infected cells would
become targets for natural killer (NK) cells (Figure 3-7). However, killing by NK cells
requires not only the loss of MHC1, but also the engagement of NK activating ligands
[45,46]. Therefore, it would be interesting to ask whether GP also sterically shields
surface MICA, MICB and ULBP proteins, which are activating ligands for the NK
receptor, NKG2D [47,48]. Effective shielding of these ligands might block the activation
and subsequent killing of targets by NK cells.
Our observations that GP may shield the surface of the viral particle require
further experimentation in two areas. The first extends from the finding that the GP
mucin and glycan cap domains limit the amount of KZ52 antibody bound to
pseudovirions, yet do not alter the neutralization profile to this antibody (Figures 4-3 and
4-4). Variations in virion surface density or arrangement of glycoproteins could vary
depending on the type of particle used to pseudotype GP. Therefore, filamentous Ebola
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VLPs should be used in neutralization assays, as they will more accurately reflect the
nature of EBOV virions. It should be noted, though, that production of VLPs gives rise to
a heterogeneous population of particles that have different morphologies. Recent work on
Marburg virus VLPs demonstrated that filamentous particles exclude host proteins that
are often incorporated into more vesicular particles, which co-purify in VLP preparations
[49]. Because the presence of host proteins may affect levels of GP incorporation,
vesicular particles need to be purified away from filamentous particles.
The finding that GP may shield the particle surface also raises the possibility that
this could help protect virions from complement-mediated neutralization. One study has
examined the sensitivity of GP-bearing pseudovirions and found them to be sensitive to
complement [50]. It would be interesting to ask whether complement sensitivity is altered
by the presence of the mucin and glycan cap domains. It is possible that steric shielding
could effectively prevent the deposition of complement components, an effect that would
perhaps be more pronounced with VLPs.
These additional experiments and future directions will help clarify the
mechanism by which GP sterically shields proteins in the surrounding membrane. They
will also begin to query the role that GP-mediated cytopathology plays in viral
pathogenesis and potentially illuminate new ways in which EBOV counters the immune
response. Ultimately, the best method to study the effects of GP-mediated cytopathology
will be the creation of EBOV with genetic deletions in the GP mucin domain and glycan
cap. This is technically feasible, as a reverse genetic system exists for EBOV [6,51].
However, EBOV containing deletions in the highly-glycosylated domains of GP could
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complicate studies of pathogenesis because of the critical roles these domains may play
in viral entry.

166

Chapter 5
5.5

References

1. Simmons G, Wool-Lewis RJ, Baribaud F, Netter RC, Bates P (2002) Ebola virus
glycoproteins induce global surface protein down-modulation and loss of cell
adherence. J Virol 76: 2518-2528.
2. Sullivan NJ, Peterson M, Yang ZY, Kong WP, Duckers H, et al. (2005) Ebola virus
glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking
pathway. J Virol 79: 547-553.
3. Yang ZY, Duckers HJ, Sullivan NJ, Sanchez A, Nabel EG, et al. (2000) Identification
of the Ebola virus glycoprotein as the main viral determinant of vascular cell
cytotoxicity and injury. Nat Med 6: 886-889.
4. Takada A, Watanabe S, Ito H, Okazaki K, Kida H, et al. (2000) Downregulation of
beta1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology
278: 20-26.
5. Chan SY, Ma MC, Goldsmith MA (2000) Differential induction of cellular detachment
by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Gen Virol 81:
2155-2159.
6. Volchkov VE, Volchkova VA, Muhlberger E, Kolesnikova LV, Weik M, et al. (2001)
Recovery of infectious Ebola virus from complementary DNA: RNA editing of
the GP gene and viral cytotoxicity. Science 291: 1965-1969.
7. Vassilieva EV, Gerner-Smidt K, Ivanov AI, Nusrat A (2008) Lipid rafts mediate
internalization of beta1-integrin in migrating intestinal epithelial cells. Am J
Physiol Gastrointest Liver Physiol 295: G965-976.
8. Ng T, Shima D, Squire A, Bastiaens PI, Gschmeissner S, et al. (1999) PKCalpha
regulates beta1 integrin-dependent cell motility through association and control of
integrin traffic. Embo J 18: 3909-3923.
9. Naslavsky N, Weigert R, Donaldson JG (2003) Convergence of non-clathrin- and
clathrin-derived endosomes involves Arf6 inactivation and changes in
phosphoinositides. Mol Biol Cell 14: 417-431.
10. Zampieri CA, Fortin JF, Nolan GP, Nabel GJ (2007) The ERK mitogen-activated
protein kinase pathway contributes to Ebola virus glycoprotein-induced
cytotoxicity. J Virol 81: 1230-1240.
11. Martinez O, Valmas C, Basler CF (2007) Ebola virus-like particle-induced activation
of NF-kappaB and Erk signaling in human dendritic cells requires the
glycoprotein mucin domain. Virology 364: 342-354.
12. Ray RB, Basu A, Steele R, Beyene A, McHowat J, et al. (2004) Ebola virus
glycoprotein-mediated anoikis of primary human cardiac microvascular
endothelial cells. Virology 321: 181-188.
13. Frisch SM, Screaton RA (2001) Anoikis mechanisms. Curr Opin Cell Biol 13: 555562.
14. Zhan M, Zhao H, Han ZC (2004) Signalling mechanisms of anoikis. Histol
Histopathol 19: 973-983.
15. Frisch SM, Francis H (1994) Disruption of epithelial cell-matrix interactions induces
apoptosis. J Cell Biol 124: 619-626.
167

Chapter 5
16. Schlaepfer DD, Hanks SK, Hunter T, van der Geer P (1994) Integrin-mediated signal
transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase.
Nature 372: 786-791.
17. Alazard-Dany N, Volchkova V, Reynard O, Carbonnelle C, Dolnik O, et al. (2006)
Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a
moderate level. J Gen Virol 87: 1247-1257.
18. Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, et al. (2008) Structure of the
Ebola virus glycoprotein bound to an antibody from a human survivor. Nature
454: 177-182.
19. Saphire EO, Dias JM, Keuhne AI, Abelson DM, Muhammad M, et al. Crystal
structure of Sudan GP reveals a shared solution for neturalizing Ebolaviruses;
2010; Tokyo, Japan.
20. Reynard O, Borowiak M, Volchkova VA, Delpeut S, Mateo M, et al. (2009)
Ebolavirus glycoprotein GP masks both its own epitopes and the presence of
cellular surface proteins. J Virol 83: 9596-9601.
21. Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM (2005) Endosomal
proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308:
1643-1645.
22. Dube D, Brecher MB, Delos SE, Rose SC, Park EW, et al. (2009) The primed
ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for
host cell binding. J Virol 83: 2883-2891.
23. Hood CL, Abraham J, Boyington JC, Leung K, Kwong PD, et al. Biochemical and
structural characterization of cathepsin L-processed Ebola virus glycoprotein:
implications for viral entry and immunogenicity. J Virol 84: 2972-2982.
24. Kaletsky RL, Simmons G, Bates P (2007) Proteolysis of the Ebola virus
glycoproteins enhances virus binding and infectivity. J Virol 81: 13378-13384.
25. Shedlock DJ, Bailey MA, Popernack PM, Cunningham JM, Burton DR, et al.
Antibody-mediated neutralization of Ebola virus can occur by two distinct
mechanisms. Virology 401: 228-235.
26. Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, et al. (2006) Role of
endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J Virol
80: 4174-4178.
27. Wesseling J, van der Valk SW, Hilkens J (1996) A mechanism for inhibition of Ecadherin-mediated cell-cell adhesion by the membrane-associated mucin
episialin/MUC1. Mol Biol Cell 7: 565-577.
28. Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J (1995) Episialin
(MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular
matrix components. J Cell Biol 129: 255-265.
29. Fukuda M (2002) Roles of mucin-type O-glycans in cell adhesion. Biochim Biophys
Acta 1573: 394-405.
30. Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and control of
the cell surface. Nat Rev Cancer 4: 45-60.

168

Chapter 5
31. Komatsu M, Carraway CA, Fregien NL, Carraway KL (1997) Reversible disruption
of cell-matrix and cell-cell interactions by overexpression of sialomucin complex.
J Biol Chem 272: 33245-33254.
32. Komatsu M, Yee L, Carraway KL (1999) Overexpression of sialomucin complex, a
rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer
cells. Cancer Res 59: 2229-2236.
33. van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ, Buijs F, Vos HL, et al.
(1993) Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J
Immunol 151: 767-776.
34. Baize S, Leroy EM, Georges-Courbot MC, Capron M, Lansoud-Soukate J, et al.
(1999) Defective humoral responses and extensive intravascular apoptosis are
associated with fatal outcome in Ebola virus-infected patients. Nat Med 5: 423426.
35. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, et al. (2004) Analysis of
human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan)
hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol
78: 10370-10377.
36. Reed DS, Hensley LE, Geisbert JB, Jahrling PB, Geisbert TW (2004) Depletion of
peripheral blood T lymphocytes and NK cells during the course of ebola
hemorrhagic Fever in cynomolgus macaques. Viral Immunol 17: 390-400.
37. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, et al. (2003) Pathogenesis
of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic
cells are early and sustained targets of infection. Am J Pathol 163: 2347-2370.
38. Mahanty S, Hutchinson K, Agarwal S, McRae M, Rollin PE, et al. (2003) Cutting
edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa
viruses. J Immunol 170: 2797-2801.
39. Bosio CM, Aman MJ, Grogan C, Hogan R, Ruthel G, et al. (2003) Ebola and
Marburg viruses replicate in monocyte-derived dendritic cells without inducing
the production of cytokines and full maturation. J Infect Dis 188: 1630-1638.
40. Bray M, Geisbert TW (2005) Ebola virus: the role of macrophages and dendritic cells
in the pathogenesis of Ebola hemorrhagic fever. Int J Biochem Cell Biol 37:
1560-1566.
41. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization
and escape by HIV-1. Nature 422: 307-312.
42. Bolmstedt A, Hinkula J, Rowcliffe E, Biller M, Wahren B, et al. (2001) Enhanced
immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by
manipulating N-glycosylation signals. Effects of elimination of the V3 N306
glycan. Vaccine 20: 397-405.
43. Mori K, Sugimoto C, Ohgimoto S, Nakayama EE, Shioda T, et al. (2005) Influence of
glycosylation on the efficacy of an Env-based vaccine against simian
immunodeficiency virus SIVmac239 in a macaque AIDS model. J Virol 79:
10386-10396.

169

Chapter 5
44. Bavari S, Bosio CM, Wiegand E, Ruthel G, Will AB, et al. (2002) Lipid raft
microdomains: a gateway for compartmentalized trafficking of Ebola and
Marburg viruses. J Exp Med 195: 593-602.
45. Orange JS, Fassett MS, Koopman LA, Boyson JE, Strominger JL (2002) Viral
evasion of natural killer cells. Nat Immunol 3: 1006-1012.
46. Orange JS, Ballas ZK (2006) Natural killer cells in human health and disease. Clin
Immunol 118: 1-10.
47. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, et al. (2001) ULBPs,
novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and
stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14: 123-133.
48. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, et al. (1999) Activation of NK cells
and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727729.
49. Kolesnikova L, Strecker T, Morita E, Zielecki F, Mittler E, et al. (2009) Vacuolar
protein sorting pathway contributes to the release of Marburg virus. J Virol 83:
2327-2337.
50. Ji X, Olinger GG, Aris S, Chen Y, Gewurz H, et al. (2005) Mannose-binding lectin
binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus
interaction with DC-SIGN and complement-mediated virus neutralization. J Gen
Virol 86: 2535-2542.
51. Neumann G, Feldmann H, Watanabe S, Lukashevich I, Kawaoka Y (2002) Reverse
genetics demonstrates that proteolytic processing of the Ebola virus glycoprotein
is not essential for replication in cell culture. J Virol 76: 406-410.

170

